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ABSTRACT 
This study is a seven year (01/07/08 - 30/06/15) retrospective review of the 
microbiology of deep neck infections in 52 adult patients at Chris Hani 
Baragwanath academic hospital. Micro-organisms isolated from patients with 
deep neck infections were analysed, including their antibiotic susceptibility 
patterns. The effectiveness of empiric usage of amoxicillin – clavulanic acid 
against commonly identified microbes and recommended alternative antibiotic 
usage were reviewed.The register records of 70 microscopy, culture, and 
antibiotic sensitivity results of specimens taken intraoperatively, in patients 
with deep neck infections who underwent surgical intervention, were analysed. 
Aerobic identified gram negative bacilli and streptococcus species; and 
anaerobic Prevotella, were the most frequently isolated microorganisms. 
Microbial sensitivity and resistance to amoxicillin – clavulanic acid was 
reported in 15% (n = 8) of patients with deep neck infections. Hence, the 
effectiveness of empiric usage of amoxicillin – clavulanic acid, against 
microbes commonly involved in deep neck infections in adults at Chris Hani 
Baragwanath academic hospital; cannot be proved nor disproved and is thus 
recommended as an option; alternative empiric antibiotic usage likewise 
cannot be recommended. Further periodic surveillance of microbial profiles 
and associated antimicrobial susceptibility results, in larger population 
samples of patients with deep neck infections; utilizing standardized protocols, 
is suggested. 
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1 INTRODUCTION  
 
Deep neck spaces are regions of loose connective tissue filling areas between the 
three layers of deep cervical fascia, namely superficial, middle and deep layers. The 
superficial layer is the investing layer. The pretracheal layer is the intermediate layer 
and the prevertebral layer is the most deep layer.1 Deep neck spaces are classified 
into three anatomic groups, relative to the hyoid bone: 
 Those located above the level of the hyoid (peritonsillar, submandibular, 
parapharyngeal, masticator/temporal, buccal, and parotid spaces) 
 Those that involve the entire length of the neck (retropharyngeal,  
prevertebral, and carotid spaces) 
 The anterior visceral, or pretracheal space located below the hyoid.2 
 
Deep neck infection (DNI) is defined as infection in the potential spaces and actual 
fascial planes of the neck.3 Once the natural resistance of fascial planes are 
overcome, spread of infection occurs along communicating fascial boundries.2 
Patterns of spread occur as abscess formation, cellulitis and necrotizing fasciitis.4 
Different classification systems for DNIs exist in the literature: One example is that of 
specifically categorizing deep neck abscesses into six groups according to abscess 
location to clarify the causal relationship and complication risk.5
                                                        
 
1.1 Literature review 
Since the discovery of penicillin, the widespread use of antibiotics has dramatically 
reduced the incidence of DNIs.6 More recent trends include the increasing 
prevalence of resistant bacterial strains, a decline in DNIs caused by pharyngitis or 
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tonsillitis, and a relative increase in DNIs of odontogenic origin.7 Low socioeconomic 
status and poor oral hygiene have been associated with higher rates of odontogenic 
infections, including Ludwig’s angina.2 Moreover, there is an increase in global 
obesity as part of the metabolic syndrome. Patients with diabetes mellitus and HIV 
infection are at risk for atypical and more complicated DNIs.2 Hence, the prevalence 
pattern of bacteria is possibly changing, and if so, the initial empiric antibiotic therapy 
for DNIs must appropriately be changed, to remain effective.  
 
Previous MMED studies conducted at CHBAH and allied hospitals have used the 
population of greater Johannesburg and Soweto for their retrospective microbiology 
review. Of note, is a prospective MMED comparative study of potential risk factors 
between Ludwig’s angina and localised odontogenic abscesses. The study was done 
on patients presenting to the maxillo-facial surgery clinics, and casualties at Charlotte 
Maxeke Johannesburg Academic Hospital (CMJAH) and Chris Hani Baragwanath 
Academic Hospital (CHBAH). The purpose of the study was, amongst others, also to 
compare the micro-organisms involved in the two infections. Findings were that 
highly virulent bacteria such as Staph aureus and Porphyromonas/ Prevotella are 
responsible for the infection that develops in Ludwig’s angina. Anaerobic bacteria 
isolated from Ludwig’s angina were resistant to erythromycin and aerobic bacteria, to 
carbinicillin.8  
 
The most frequent DNI is peritonsillar abscess, followed by submandibular, parotid, 
parapharyngeal, retropharyngeal, masseteric and pterygomaxillary abscesses and 
finally Ludwig’s angina.9This is in contrast to a report of a decline in DNIs caused by 
tonsillitis or pharyngitis.2 Nevertheless, in most cases, the source of the infection is a 
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periapical infection of the mandibular second or third tooth i.e. of odontogenic origin, 
or tonsillitis.1 A case report on a patient with a left submandibular abscess with 
underlying tongue squamous cell carcinoma and neck metastasis has been 
published.10 Also reported in the literature, is that an estimate of 22% of DNIs in 
adults, are idiopathic.9 
  
The microbiology of DNIs are similar, reflecting normal endogenous upper 
aerodigestive tract flora. Thus no correlation usually exists between the anatomic site 
and microbiology of infection.11 Of note however, is infection in the prevertebral 
space. Spread of infection to this space can be primarily haematogenous and thus 
their pathogenesis and microbiology is different, usually a predominance of 
Staphylococcus aureus and anaerobes playing a minor role. Special mention of TB 
infection in Pott’s disease can result in complications such as local vertebrae or disc 
destruction with spinal instability, or a psoas abscess distally.12 Coaggregation of 
microbes promotes plaque biofilm formation on the tooth surface.  The microbial shift 
that occurs with plague progression and various associated odontogenic infections 
have been described.1 
 
Most DNIs are polymicrobial. Only 5% are purely aerobic and 25% with isolated 
anaerobes.4 From a resource perspective, the utility of cultures have been 
questioned, with some reports indicating that culture and sensitivity data do not lead 
to a change in antibiotic selection or treatment.4 Recommendations for cultures 
include extensive or rapidly spreading infections, necrotizing and gas-forming 
infections, nosocomial or recurrent infections, and in the immuno-compromised host.4 
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The use of cultures is also supported due to the ever increasing possibility of drug-
resistant organisms.4 
 
The number of negative or contaminated cultures are not negligible, in the literature. 
One study reported 18.8% of cultures, as negative and 1.1%, as contaminated.9  
Negative cultures may be due to high dose of IV antibiotics prior to surgical drainage 
of DNIs.3 Errors during sample collection, as occur with anaerobes when the sample 
is taken using a syringe containing air, may also be a contributing factor.9 Of note is 
that anaerobes are fastidious and thus difficult to culture and are often overlooked. 
Their exact role in disease is difficult to ascertain due to inconsistent methods used 
for isolation and identification.4 Some studies concur with the above.1 However, in an 
analysis of 233 patients with DNIs, gram positive anaerobic cocci were most often 
isolated.14 Blood cultures have a low positive rate of 15.5% and are thus assumed to 
have little impact on the management of deep neck abscesses, in particular, as 
compared to pus cultures.3 Molecular techniques, e.g. sequence-based analysis, 
such as 16S rRNA, have been advocated for organisms that are poorly cultivable or 
for identification when traditional phenotypic methods have failed. 15  
 
Earlier studies emphasised Streptococcus pyogenes, Staphylococcus aureus and 
anaerobes as predominant organisms in DNIs.16 Although anaerobic cultures were 
not done in all cases , one study reported that gram negative organisms have 
replaced haemolytic Streptococcus as the dominant pathogen in deep neck 
abscesses.16  
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In a study of 365 cases of DNIs, Streptococcus viridans, Coagulase-negative 
staphylococcus, Staphylococcus aureus and Klebsiella pneumoniae were found to be 
the most prevalent aerobic organisms. Bacteroides, Peptostreptococcus, 
Fusobacterium and Prevotella were the most prevalent anaerobes, in descending 
order respectively.1 Another study reported similar results in an analysis of 634 
patients.17 Factors predictive of severe DNIs are streptococcus infections, presence 
of tonsils, education level and geographic location.18 
                                                                                                                                                                                                             
Community-associated methicillin-resistant Staphylococcus aureus (MRSA) isolation 
is increasingly common, especially in IV drug abusers and immune-compromised 
patients and may play an increasing role in DNIs in the near future.1 This organism is 
recognised as a nasal coloniser.12 One  study reports on a patient, with MRSA 
necrotising fasciitis that originated at the base of the nose, who eventually had a 
reconstruction with a radial forearm free flap.4 In certain geographical areas MRSA is 
an emerging pathogen in necrotising fasciitis and descending mediastinitis.2 Of 
interest, is a case report of an 88 year old man with a mycotic pseudoaneurysm of 
the common carotid artery mimicking a parapharyngeal abscess. The causative 
organism was community acquired MRSA.19 
 
Klebsiella pneumonia is the most common causative pathogen in diabetic patients 
with DNIs.3 Diabetes mellitus and multiple deep neck space involvement are the 
strongest independent predictors of complications.1 In another study, the 
Streptococcus milleri group (SMG) was identified in 33% of DNIs. Of note is that the 
SMG infection spreads rapidly and is also suspected to be involved in systematic 
purulent diseases e.g. empyema, hepatic and cerebral abscesses.5 Lemierre’s 
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syndrome (septic internal jugular vein thrombophlebitis) complicates 1% or less of 
DNIs, most commonly in young adults. Approximately 80% of cases are associated 
with Fusobacterium necrophorum bacteremia.21   An analysis of 118 case reports 
found that the commonest metastatic focus is the lung followed by joints. The overall 
mortality was 6%.21 In patients with deep neck abscesses, factors related to mortality 
were: Multiple deep neck space involvement (p < 0.01), bilateral involvement (p < 
0.05) and reoperation (p < 0.001); 40 % of these patients had comorbidities, with 
diabetes mellitus being the commonest, found in 34% of patients.20 
                                                                                            
With regards to the influence of the patient’s age on DNIs, odontogenic and salivary 
origin are the most common sources of infection for the elderly (>65 years of age). 
Compared to the adult group (>18 years of age), elderly patients with DNIs had more 
multiple space involvement, complications, surgical interventions and longer hospital 
stays. However, outcome in the two groups were the same. Therefore aggressive 
management for DNI should not be withheld simply because of old age.22                                                              
 
The role of atypical organisms in DNIs also needs mention. One study reported TB as 
a cause of DNI in 6.9% of patients.23 A case report of DNI caused by Salmonella 
enterica in a 46 year old man newly diagnosed with type II diabetes mellitus, has 
been published. The mechanism of spread is either haematogenous or lymphatic 
from a primary gastrointestinal infection.24 
 
Empiric antibiotic therapy with a combination of penicillin plus a beta-lactamase 
inhibitor e.g. amoxicillin/clavulanate, is recommended among other options, providing 
sufficient coverage for both anaerobic and aerobic bacteria.1 This is the current 
7 
 
practice at CHBAH. Clindamycin may no longer be considered a first-line antibiotic in 
DNIs, as current resistance rates among Bacteroides fragilis strains reach 20-50% or 
more, worldwide.1 Surgical exploration and drainage of DNIs may be mandatory in 
selected cases at presentation or in cases that fail to respond to parenteral antibiotics 
within the first 24 to 48 hours. Cultures should be done intra-operatively to establish 
the pathogen(s) involved and to obtain an antibiogram to tailor the antibiotic 
treatment.14 
 
Patients with DNI are referred to the department of Otorhinolaryngology at CHBAH, 
usually when surgical intervention is anticipated. Prompt medical treatment, with or 
without surgery, is usually initiated. Each patient is given initial empiric antibiotic 
therapy pending DNI microbiological, culture and sensitivity (MC&S) result availability 
from the National Health Laboratory Service (NHLS), when requested.  
 
Empiric therapy is based on suspected rather than known pathogens whose 
antimicrobial susceptibility patterns are predictable.25 Observed differences in the 
local prevalence of bacterial pathogens and the continued emergence of antibiotic-
resistant strains of bacteria influence the choice of antibiotic used to initiate 
treatment.26,27 This noted trend of the increasing prevalence of more resistant 
bacterial strains is the reason for this study: an audit of the prevalent bacteria 
associated with DNI is required to ascertain if the current empiric antibiotic therapy in 
use at CHBAH is effective. In essence, continued periodic surveillance testing on 
local susceptibility patterns within specific health care centres is warranted.15 
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In recent years, the incidence of DNIs has increased, but mortality has declined.9This 
has been attributed to a comprehensive, patient centred multidisciplinary approach, 
including improvements in diagnostic and therapeutic interventions, namely: airway 
control, radiological imaging, effective antibiotic usage, early surgical intervention, 
microbiology and critical care support, respectively.1, 3,  
 
1.2 Hypothesis: 
 
The empiric antibiotic therapy currently in use is effective against microbes commonly 
involved in DNIs in adults at CHBAH.  
 
1.2.1 Study objectives 
 
 The aim of the study is:  
 To determine if micro-organisms are identified in DNIs. 
 To review the types of micro-organisms commonly isolated from DNIs. 
 To determine the antibiotic sensitivity and resistance of these micro-
organisms. 
 To make recommendations on the choice of antibiotics to be used to 
initiate treatment prior to obtaining MC&S results from the NHLS. 
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2 METHODOLOGY 
 
This was a quantitative research study. 
 
2.1 Study Design 
 
This study was a retrospective review of the microbiology of DNIs. 
 
2.2  Study Population 
 
This study included all patients with DNIs from whom specimen microbiology 
samples were taken, comprising: 
                                                         
 Inclusion criteria 
- All adult patients 18 years or older 
- Diagnosed with DNI                                         
- Required surgical intervention 
- For whom DNI MC&S were obtained. 
      
 Exclusion criteria 
    All patients with DNI: 
- Extended into the mediastinum on CT – these patients were 
transferred for surgery to another hospital which, unlike CHBAH, had 
cardiothoracic surgical staff.                                        
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- Who had only active medical management of DNI with/without 
aspirates submitted for microbial analysis, ie not intra-operatively 
- Who had surgery performed by other surgical departments. 
                                         
2.3 Study Location 
 
The otorhinolaryngology clinical units of CHBAH in Gauteng. This is a tertiary referral 
hospital affiliated to the University of the Witwatersrand. 
 
 2.4 Study Period 
 
The study extended over a period of 7 years, from 01/07/08 to 30/06/15. 
                                                        
 2.5 Data Collection 
 
 Patients were identified from three sources: 
 ENT operating theatre register 
 ENT ward registers (admissions, discharge and mortality) 
 Radiology CT scan registers 
 
The operating theatre register was used as the primary reference to identify patients. 
The ENT ward registers and the radiology CT scan registers were used as secondary 
references to identify patients, whose theatre records were inadequate (misspelt 
names/ incorrect hospital numbers, or whose records were illegible at places).The 
secondary references were used as a screen to source for patients whose 
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information had not been identified specifically in the ENT theatre register, e.g. 
patients whose first surgical procedures were recorded but not their relook 
procedures; and vice versa as well as for those patients for whom the first surgical 
procedures and relook procedures were not recorded in the theatre register. 
 
Eligible patients correctly identified from the theatre register were recorded as an 
initial sample population. This information, i.e., patients’ hospital numbers/full names, 
was then used to search the NHLS database for the results of specimens sent  for 
MC&S. Requested histology reports were also obtained. The NHLS database was 
accessed online, either via a personal or hospital owned computer; with a personal 
username and password. Thus the names and records obtained from the NHLS 
database was password protected, remained confidential for ethical purposes. The 
relevant information was extracted and all findings were recorded into one of the 
following categories: 
 
 Positive culture – micro-organism/s were identified, i.e growth 
 Negative culture –  the report stated “no bacterial growth” 
 No results – no specimen MC&S results were found in the database 
 Rejected specimens – these specimens were unsuitable for processing                                              
 Incomplete or incorrect information – not sufficient information was available 
from the registers to search the NHLS database or the NHLS database 
information per se was not found to be useful. 
 Histology results – a histological analysis, not a microbiological analysis, was 
done on the specimen. 
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Patients identified exclusively from the secondary references were cross-checked 
against their recorded microbiological laboratory reports, and were  included in the 
study population. If “rejected specimens”, “no results” or “incomplete or incorrect 
information” was found, then these were excluded from the final study population. 
The following were recorded, for each patient, on the data collection sheets (see 
appendix IA, IB):                                                                                                                                  
 Hospital registration number (This was kept confidential- did not appear in the 
data collection sheets submitted in this final research report.)  
 Name & Surname. (This was kept confidential)   
 Date of surgery for DNI 
 Gender  
 Age 
 Type of isolated microorganism 
 Antibiotic sensitivity & resistance 
 Histological  analysis done, or not                                               
 Tissue necrosis reported on histological analysis, or not 
 All data was captured on Microsoft Excel Spreadsheet. 
                    
2.6 Ethical Considerations 
                                                        
All patient information was kept strictly confidential. Ethical approval was obtained 
from the Human Research Ethics Committee of the University of the Witwatersrand. 
The Ethics Certificate was presented as appendix II. No patient consent was 
required, as this was a retrospective review. 
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2.7 Problems and Potential Limitations 
 
This study was conducted at CHBAH, which is the largest hospital in Africa: All 
information was not meticulously captured and some data was collected from patient 
records that were not well managed, for example, files went missing at times. Thus 
accessing all information was at times laborious, as this was a retrospective data 
collection process. 
                                                       
A sample size of 50-55 patients with DNIs, who fell into the inclusion category of data 
collection; was given. No significant findings were possible due to this small size. To 
accommodate inadequate patient records and patient numbers, the initial 3 year 
study period from 01/07/’12 – 30/06/’15 was prolonged retrospectively to 01/07/’08. 
This 7 year study period was to ensure that the minimum target sample population of 
50-55 patients, was obtained. However, a sample size calculation was not necessary 
for this retrospective audit, over a fixed time period. Not all patients with DNIs were 
accounted for: Those treated with active medical management only; those with more 
advanced disease, e.g. mediastinitis; or patients managed by other departments, e.g. 
DNI of odontogenic origin treated by Maxillo-facial surgery staff; thus a selection bias 
was favoured.   
                                                          
2.8 Data Analysis 
 
Standard statistical methods were used for analysis. To determine the statistical 
significance of findings, probability values were calculated. A probability value of 
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p < or = 0.05 was regarded as significant. Statistical values such as mean, median, 
range, minimum, maximum, standard deviation and standard error etc. were 
calculated for age, gender, antibiotic sensitivity/resistance patterns and histograms 
were drawn. The bacterial profile in male patients were compared to female patients 
for various variables as seen in the tables, and its statistical significance was 
determined.  Chi Square test and Student’s t-test were used to determine statistical 
significance.  
 
 Use was made of the following software: 
 Microsoft Word 2013 Word Processor for all typing requirements. 
 Microsoft Excel 2013 Spreadsheet for data storage, manipulations and 
analysis. It was also used for statistical calculations, as mentioned above. 
 Web Chi Square calculator for comparison of sample population.28 
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3 RESULTS AND ASSOCIATED DISCUSSION 
 
3.1 Analysis of the Study Population and Study Period 
 
Analysis of the study population:  
 
For the three year study period 01/07/’12 – 30/06/’15, a total of 63 adult patients with 
DNIs were obtained from the registers. The 63 patient hospital clinical records were 
then requested for, and DNI inclusion criteria were verified as per clinical findings, 
radiological investigations and or theatre notes captured: 
                                                               
There were 6 patient records not accessible. A total of 57 patient hospital clinical 
records were accessed. From these records, 33 patients met inclusion criteria and 24 
patients were thus excluded. 
 
From the 24 patients  excluded: 
 17 patients did not have DNIs 
 6 patients did not have MC&S specimens submitted to the NHLS or MC&S 
results were not available in the NHLS database 
 1 patient was not an adult with DNI 
 
For the 6 patients whose records were not accessible:  
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After cross-checking patient register details against their NHLS reports, 2 patients 
met inclusion criteria. Thus 4 patients were excluded due to no hospital clinical 
records being available.  
 
In total, 28 patients were excluded. In total, 35 patients were included. These patients 
contributed 47 specimen MC&S results from initial and relook surgical procedures. 
 
The study period was prolonged retrospectively to 01/07/08; to ensure that 50 – 55 
patients with DNIs were included in the study, as per protocol. 
                                                                      
For the 4 year study period 01/07/’08 – 30/06/’12, a total of 32 adult patients with 
DNIs, at CHBAH, were obtained from the registers. The 32 patient hospital clinical 
records were then requested for, and DNI inclusion criteria were verified as per 
clinical findings, radiological investigations and or theatre notes captured: There were               
4 patient records not accessible. A total of 28 patient hospital clinical records were 
accessed. From these records, 17 patients met inclusion criteria, thus 11 patients 
were excluded. 
 
From the 11 patients excluded: 
 3 patients did not have DNIs 
 4 patients did not have MC&S specimens submitted to the NHLS or MC&S 
results were not available in the NHLS database 
 4 patients had surgeries performed for DNIs by other surgical departments 
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In total, 15 patients were excluded. The 17 patients included, contributed 23 
specimen MC&S results from initial and relook surgical procedures. 
 
For the seven year study period  01/07/’08 – 30/06/’15,  a total of: 
        95 patients (63+32)                  : From registers 
        8 patients   (4 + 4)                    : Records not accessed 
        87 patients (59+28)                  : Records accessed 
        43 patients [(24+4) + (11+4)]   : Excluded 
        52 patients [(33+2) + (17)]       : Included 
                                                          
Analysis of patient admissions over the study period (01/07/2008 – 30/06/2015) 
 
Table 3.1   52 patient admissions over the 7 year study period (01/07/2008 – 
30/06/2015) 
 
 
Year No.      Duration No. of Patients 
1 01/07/2008-30/06/2009 6 
2 01/07/2009-30/06/2010 4 
3 01/07/2010-30/06/2011 6 
4 01/07/2011-30/06/2012 1 
5 01/07/2012-30/06/2013 8 
6 01/07/2013-30/06/2014 9 
7 01/07/2014-30/06/2015 18 
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During the initial 3 years of the study period (01/07/2008 – 30/06/2011), patient 
admissions were relatively constant, varying between 4 and 6 patients per year. In 
the fourth year of the study period (01/07/2011 – 30/06/2012), patient admissions 
noticeably declined, followed by a significant increase in patient admissions during 
the final 3 years of the study period (01/07/2012 – 30/06/2015) (p<0.05); with an 
absolute doubling in patient admissions during the final year (01/07/2014 – 
30/06/2015) relative to the preceding year (01/07/2013 – 30/06/2014). 
 
3.1.1 Analysis of age distribution of 52 patients 
 
Table 3.2 Age statistics of all patients 
Statistic Value 
Mean 40.9 
Median 39 
Mode 28 
Std. Deviation 15.5 
Kurtosis -0.61 
Skewness 0.5 
Minimum 19 
Maximum 77 
Count 52 
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Figure 3.1 Age distribution of 52 patients  
 
The age distribution of patients ranged from 19 to 77 years with a mean of 40.9 (+ -
15.5) yrs.  
 
3.1.2 Analysis of gender distribution of 52 patients 
 
Table 3.3 Gender distribution of all patients 
Males 33 63% 
Females 19 37% 
Total 52 100% 
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Figure 3.2 Gender distribution of 52 patients 
 
The study population comprises 63% (n=33) males and 37% (n=19) females. The 
ratio of males: females is 1.74:1. 
 
3.1.3 Analysis of 70 specimen microbiological cultures in patients with DNIs  
 
The 52 patients contributed 70 (47 + 23) specimen MC&S results from initial and 
relook surgical procedures. In addition, some patients had more than one specimen 
MC&S result per surgical procedure for DNI. One specimen was categorized as a 
‘rejected specimen’- due to a lab error. This is depicted with “ – “ in Appendix IA. For 
10 (6+4) patients, specimens were categorised as ‘no results found’. No specimen 
was categorized as ‘incomplete or incorrect information’. 
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Table 3.4 Categorization of microbiological culture results from 70 specimens of 52 
patients with DNIs 
 
 
 
 
 
                                                         
                                                            
  
 
  
 
 
 
 
 
 
Figure 3.3 Culture distribution of specimens 
 
The distribution of positive cultures is 69% (n=48) and that of negative cultures is 
31% (n=22), from 70 specimens of 52 patients with DNIs. This percentage of 
negative cultures is not negligible; higher than that quoted in some studies and lower 
than that in others, 19% and 52% respectively.1,9 Possible explanations include 
Result 
category 
No. of 
specimens 
% 
Positive 
cultures 
48 69 
Negative 
cultures 
22 31 
Total  70 100 
69%
31%
Culture distribution
Positive cultures Negative cultures
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errors in sample collection and processing, fastidious growth patterns and pre – 
operative empiric antibiotic usage.1,3,4,9  
.                                                     
 
Figure 3.4 Age distribution per positive & negative cultures of patients 
 
The age distribution per positive cultures of patients is that of 69% (n=33) between 
the ages of 21 and 55 with a peak incidence of 19% (n=9) in the age category 51-55, 
followed by a second peak incidence of 15% (n=7) in the age category 21-25. The 
age distribution per negative cultures of patients is that of 82% (n=18) between the 
ages of 26 and 55 with a peak incidence of 32% (n=7) in the age category 26-30. The 
Student’s t-test for age distribution per positive and negative cultures of patients   
revealed no significant difference (p>0.05). 
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Table 3.5 Gender distribution per positive & negative cultures of patients 
  Subtotals Totals 
FEMALE PATIENTS No. of patient specimens   
POSITIVE CULTURES:    
- initial surgical procedure 12   
Additional specimens:    
- initial surgical procedure                      4   
- relook surgical procedure 1 17  
NEGATIVE CULTURES:    
- initial surgical procedure 7   
Additional specimens:    
- initial surgical procedure                                           1   
- relook surgical procedure 0 8 25 
MALE PATIENTS    
POSITIVE CULTURES:    
- initial surgical procedure 22   
Additional specimens:    
- initial surgical procedure                                                                3   
- relook surgical procedure 6 31  
NEGATIVE CULTURES:    
- initial surgical procedure 11   
Additional specimens:    
- initial surgical procedure                                                                                      3   
- relook surgical procedure 0 14 45 
TOTAL    70 
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Table 3.6 Gender distribution per positive & negative cultures of patients: 
Categorisation of the results from 70 specimens 
Result category No. of patient 
specimens 
% 
Females: Positive 
cultures 
17 24.3 
Females: Negative 
cultures 
8 11.4 
Males: Positive 
cultures 
31 44.3 
Males: Negative 
cultures 
14 20 
Total 70 100% 
                                                 
24.3%
11.4%
44.3%
20%
Gender Distribution per Cultures of Patients
Females: positive cultures
Females: negative cultures
Males:      positive cultures
Males:      negative cultures
 
Figure 3.5 Gender distribution per positive & negative cultures of patients 
 
The gender distribution per positive cultures of patients comprises 24.3% (n=17) 
females and 44.3% (n=31) males. The gender distribution per negative cultures of 
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patients comprises 11.4% (n=8) females and 20% (n=14) males. The Student’s t-test 
for gender distribution per positive and negative cultures of patients revealed no 
significant difference (p>0.05). 
 
3.2 Analysis of Microbiological Cultures per Absolute Patient Count 
 
Table 3.7 Categorisation of microbiological culture results in 52 patients; per 
absolute patient count 
Result 
category 
No. of 
patients 
% 
Positive 
cultures 
36 69 
Negative 
cultures 
16 31 
Total  52 100 
 
The distribution of positive cultures is 69% (n=36) and that of negative cultures is 
31% (n=16), per absolute count of 52 patients with DNIs.  
 
An aerobic gram positive coccus was isolated in 1 patient with a positive culture, 
however, the microorganism was non-viable (Appendix 1A) and will thus be 
preferably excluded: Total number of patients with positive cultures will be depicted 
as *35 in calculations to follow. 
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Table 3.8. Comparison of frequency of isolation of different microbiological 
categories of microorganisms in *35 patients with positive cultures; per absolute 
patient count 
Microbiological 
category 
Frequency % 
Aerobes only 31 89 
Aerobes & Anaerobes  4 11 
Anaerobes only 0 0 
Total *35 100% 
 
Table 3.9 Number of different microorganisms identified per patient distribution, 
expressed as absolute numbers and percentages of the total study population with 
positive cultures 
No. of different 
microorganisms 
per patient 
No. of 
patients 
% of 
patient 
total 
1 23 66 
2   5 14 
3   4 11 
4   3 9 
Total  *35 100% 
  
                                                              
 
27 
 
Table 3.10 All pathogens: 57 microorganisms identified on culture in 35 patients, 
expressed as absolute numbers and percentages of the total  
 
 
 
 
 
 
Microorganisms  No. % of Total 
Aerobes     
ACIBA 6 10.5 
STRPY 4 7 
STRAN 4 7 
CNS 3 5.3 
STRGF 3 5.3 
ENTFA/ENCFE 4 7 
STRSP 2 3.5 
STRMI 3 5.3 
STAHA 2 3.5 
MOGMO 1 1.8 
KLESP 3 5.3 
STRVI 2 3.5 
ENTCL 2 3.5 
CANAL 1 1.8 
CITFR 1 1.8 
CORSP 1 1.8 
ESCCO 1 1.8 
HAEPA 1 1.8 
SALSP 2 3.5 
SERSP/SERMA 2 3.5 
AFB 1 1.8 
STAEP 1 1.8 
STAAU 2 3.5 
STEMA 1 1.8 
   
Anaerobes   
Prevotella 3 5.3 
CORSP 1 1.8 
   
TOTAL 57 100 
Summary:   
Aerobes  53 93 
Anaerobes 4 7 
28 
 
There were 26 different microorganisms isolated and identified on culture. Of these, 
92% (n=24) of microorganisms were aerobic and 8% (n=2) anaerobic. The most 
frequently isolated aerobic microorganisms, in descending order, were Acinetobacter 
baumannii (ACIBA) ; Streptococcus pyogenes (STRPY), Streptococcus anginosus 
(STRAN), Enterococcus faecalis / Enterococcus faecium (ENTFA/ENCFE); 
Coagulase negative staphylococcocus (CNS), Streptococcus Group F (STRGF), 
Streptococcus milleri (STRMI), Klebsiella (KLESP); respectively. Prevotella was the 
most frequently isolated anaerobic microorganism, in keeping with the literature.1,16,17  
 
Thus, when considered in isolation, gram negative bacilli (GNB) (ACIBA) were the 
dominant micro – organisms in DNIs, however when clustered, GNB : Streptococcus 
species approximated 1:1, which is not in keeping with the literature.16 Aerobic : 
anaerobic  isolation & identification of the above more frequently occurring micro – 
organisms were in the order of 10:1.  
 
A total of 33% (1 in 3) of patients with KLESP DNIs had diabetes mellitus type II, and 
presented in a state of diabetic ketoacidosis. Although infrequently encountered, 
atypical micro – organisms in this patient population included fungi, TB and 
salmonella, in keeping with the literature.23,24   
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Table 3.11 23 microorganisms identified on culture as single pathogens in 23 
patients, expressed as absolute numbers and percentages of the total                       
Microorganisms No. % of Total 
Aerobes     
STRPY 3 13 
STRAN 3 13 
STRSP 2 8.7 
MOGMO 1 4.4 
STRGF 2 8.7 
CANAL 1 4.4 
CNS 1 4.4 
ENTFA/ENCFE 1 4.4 
STRVI 1 4.4 
ESCCO 1 4.4 
STRMI 1 4.4 
SALSP 2 8.7 
STAAU 2 8.7 
STEMA 1 4.4 
AFB 1 4.4 
   
Anaerobes 0 0 
   
TOTAL 23 100 
Summary:   
Aerobes  23 100 
Anaerobes 0 0 
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Table 3.12 10 microorganisms identified on culture as co-existing pathogens in 5 
patients, expressed as absolute numbers and percentages of the total 
 
 
 
 
 
 
 
 
 
 
 
Table 3.13 12 microorganisms identified on culture as one of three pathogens in 4 
patients, expressed as absolute numbers and percentages of the total   
Microorganisms No. 
% of 
Total 
Aerobes:      
ACIBA 3 25 
ENTFA/ENCFE 1 8.3 
KLESP 2 16.7 
HAEPA 1 8.3 
STAHA 2 16.7 
STRPY 1 8.3 
STRVI 1 8.3 
   
Anaerobes:   
Prevotella 1 8.3 
   
TOTAL 12 100 
Summary:   
Aerobes  11 91.7 
Anaerobes 1 8.3 
                                                                
Microorganisms No. % of Total 
Aerobes:     
ACIBA 2 20 
CITFR 1 10 
CNS 1 10 
ENTFA/ENCFE 1 10 
ENTCL 1 10 
SERSP/SERMA 1 10 
STRMI 1 10 
KLESP        1                   10 
   
Anaerobes:   
Prevotella 1 10 
   
TOTAL 10 100 
Summary:   
Aerobes  9 90 
Anaerobes 1 10 
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Table 3.14 12 microorganisms identified on culture as one of four pathogens in 3 
patients, expressed as absolute numbers and percentages of the total  
Microorganisms No. 
% of 
Total 
Aerobes:      
ACIBA 1 8.3 
CNS 1 8.3 
CORSP 1 8.3 
ENTFA/ENCFE 1 8.3 
ENTCL 1 8.3 
SERSP/SERMA 1 8.3 
STAEP 1 8.3 
STRAN 1 8.3 
STRMI 1 8.3 
STRGF 1 8.3 
   
Anaerobes:   
Prevotella 1 8.3 
CORSP            1         8.3 
   
TOTAL 12 100 
Summary:   
Aerobes  10 83 
Anaerobes 2 16.6 
 
Table 3.15 Comparison of frequency of isolation of different microbiological 
categories of microorganisms between clusters of patients with different numbers of 
microorganisms identified     
No. of different 
microorganisms 
per patient  
Aerobes Anaerobes Total 
1 23 0 23 
2 9 1 10 
3 10 2 12 
4 10 2 12 
TOTAL 52 5 57 
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Using the Chi Squared Distribution, a significant difference (p < 0.05) was found in 
the relative distribution of aerobes and anaerobes amongst the above 4 clusters of 
patients, including a comparison of monomicrobial relative to polymicrobial growth 
identification. This is most probably due to only aerobic microorganisms (n=23) 
identified in monomicrobial growth patterns without any anaerobic growth (n=0),  
whilst in polymicrobial growth patterns, a higher proportion of aerobic (n=29) relative 
to anaerobic (n=5) microorganisms were identified.  
 
Thus when all pathogens were considered, polymicrobial growth was more common 
than monomicrobial growth patterns; 60% (n=34) and 40% (n=23), respectively 
(Table 15), in keeping with the literature.4 However, 66% (n=23) of patients with 
positive cultures had monomicrobial growth identification with polymicrobial growth in 
only 34% (n=12) (Table 9). In a study of 365 patients, 49% (n=177) of cultures were 
positive, with only 16% polymicrobial.1   Of note, in this study of 35 patients with 
positive cultures, 89% (n=31) had only aerobic growth and in only 11% (n=4), 
polymicrobial growth of aerobes and anaerobes were identified (Table 8); which is 
not in keeping with some literature.4  However, in another study of 634 patients, the 
bacteriology of DNIs was polymicrobial; 81% (n=514) of cultures were positive, only 
aerobes isolated in 39%, polymicrobial growth of aerobes and anaerobes in 32% and 
only anaerobes in 10%.17  
 
In this study, when all pathogens were considered, 93% (n= 53) were aerobic and 
7% (n=4) anaerobic (table 10). Whether this represents a true reflection of anaerobes 
involved in DNIs; or an underestimation secondary to intraoperative specimen 
collection, laboratory processing or culture methods; requires further 
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clarification.1,4,9,14,16 The incidence of anaerobic bacteria is higher in adults, DNIs of 
dental origin and in non diabetic patients.17  
 
Boscolo – Rizzo discussed that there has been an increase in anaerobic bacteremias 
with multiple - drug - resistant organisms; as there is an increasing population with 
multiple comorbidities and compromised immune systems; that anaerobes express 
virulent factors that may promote localised infection dissemination and by producing 
beta – lactamase, are able to protect themselves and other penicillin – susceptible 
organisms from the activity of penicillins. He emphasised the importance and 
described the correct method of anaerobic specimen collection, transport and 
processing.1   
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Table 3.16 Distribution of 57 identified microorganisms in 33 male and 19 female 
patients 
Microorganisms Males Females 
Aerobes:   
ACIBA 3 3 
STRPY 2 2 
STRAN 3 1 
CNS 3 0 
STRGF 3 0 
ENTFA/ENCFE 2 2 
STRSP 2 0 
STRMI 1 2 
STAHA 0 2 
MOGMO 1 0 
KLESP 1 2 
STRVI 1 1 
ENTCL 2 0 
CANAL 0 1 
CITFR 1 0 
CORSP 0 1 
ESCCO 1 0 
HAEPA 0 1 
SALSP 1 1 
SERSP/SERMA 2 0 
AFB 1 0 
STAEP 0 1 
STAAU 2 0 
STEMA 1 0 
   
Anaerobes:   
Prevotella 1 2 
CORSP          0             1 
   
TOTAL 34 23 
Summary:   
Aerobes  33 20 
Anaerobes 1 3 
 
No significant difference (p>0.05) was found on comparative distribution of aerobes 
and anaerobes amongst male and female patients.  
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Figure 3.6 Comparative distribution of other gram positive and gram negative 
microorganisms isolated on microscopy only 
 
Apart from the microorganisms isolated on microscopy and identified on culture, 
other gram positive cocci, gram negative bacilli and gram positive bacilli were 
isolated on microscopy, however not identified on culture (Figure 3.6 & Appendix 1B). 
 
This is possibly attributed to the fastidiousness inherent to the microorganisms, 
particularly anaerobes.4 Delays in timeous specimen analysis due to hospital 
resources constraints may have been contributory: Gram positive cocci 3+ were 
isolated on microscopy from 2 specimens of a patient however in both instances the 
microorganisms lost viability (Appendix 1B). Other probabilities include inadequate  
methods of specimen collection and transport or unfavourable culture mediums. Pre-
operative intravenous antibiotic therapy duration could have also been instrumental. 
Notably, antibiotic sensitivity and resistance patterns are not reported for 
microorganisms isolated on microscopy and not identified on culture. This most likely 
has therapeutic implications on the correct usage of empiric and directed antibiotics 
or rather lack thereof in the medical management of patients with DNIs. The 
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significance of this in the context of not only diagnostic but also definitive therapeutic 
surgical management of patients with DNIs and its impact on mortality versus overall 
survival regardless, warrants further research. One could then also question the 
overall cost versus benefit of intra operative specimen collection for MC&S testing in 
patients with DNIs. 
 
3.3 Antibiotic Sensitivity and Resistance Profiles of Microorganisms 
 
Antibiotic sensitivity with or without resistance profiles of microorganisms were 
reported for 34 patients with positive cultures. No reports were documented for 2 
patients who cultured Candida albicans (CANAL) and Gram positive cocci (non - 
viable), respectively ( Appendix 1 B). 
 
Table 3.17 Extraction of recorded microbial sensitivity & resistance profiles per 
antibiotics 
Antibiotics Reactive Sensitivity Resistance Total 
  Microorganisms       
Ceftazidime ACIBA 3 4 7 
    [43%] [57%] [100%] 
Cefotaxime/ KLESP 2 1 3 
Ceftriaxone   [67%] [33%] [100%] 
Penicillin/ CNS 2 1 3 
Ampicillin   [67%] [33%] [100%] 
Amoxicillin- KLESP 2 1 3 
Clavulanic 
acid   [67%] [33%] [100%] 
Ciprofloxacin ACIBA 2 4 6 
    [33%] [67%] [100%] 
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Table 3.18 Reported antibiotic sensitivity profiles of microorganisms 
 
 
 
 
ANTIBIOTICS - STAHA STAEP ENTFA/ ACIBA KLESP STAAU CNS ENTCL SERMA/ 
SENSITIVITY     ENCFE           SERSP 
Penicillin/    1     2    
Ampicillin     25%       50%     
Ampicillin/               
Amoxicillin                   
Cloxacillin           2       
            67%       
Piperacillin/               1 1 
Tazobactam               20% 20% 
Amoxicillin-         2         
Clavulanic acid         40%         
Cefotaxime/         2         
Ceftriaxone 
(3rd generation 
Cephalosporin)         40%         
Ceftazidime       3           
(3rd generation 
Cephalosporin)       33.3%           
Cefepime 
(4th generation               2 2 
Cephalosporin)               40% 40% 
Erythromycin/           1       
Azithromycin           33%       
Clindamycin                   
                    
Ciprofloxacin       2       1 1 
        22.2%       20% 20% 
Ertapenem         1     1 1 
          20%     20% 20% 
Colistin       4           
        44.4%           
Vancomycin 2 1 3       2     
  100% 100% 75%       50%     
Trimethoprim- 
Sulfamethoxazole                   
                    
INH &               
Rifampicin                   
          Total 2 1 4 9 5 3 4 5 5 
38 
 
Table 3.19 Reported antibiotic sensitivity profiles of microorganisms (continuation of 
Table 3.18 above)   
 
                  
 
 
ANTIBIOTICS - MOGMO CITFR SALSP STRPY STRAN STEMA STRSP ESCCO 
SENSITIVITY                 
Penicillin/     5 4      
Ampicillin       83% 100%       
Ampicillin/             
Amoxicillin                 
Cloxacillin                 
                  
Piperacillin/     1               
Tazobactam 33.3%               
Amoxicillin-               1 
Clavulanic acid               100% 
Cefotaxime/     2       2   
Ceftriaxone 
(3rd generation 
Cephalosporin)     67%       100%   
Ceftazidime                 
(3rd generation 
Cephalosporin)                 
Cefepime 
(4th generation 1               
Cephalosporin 33.3%               
Erythromycin/                 
Azithromycin                 
Clindamycin       1         
        17%         
Ciprofloxacin     1           
      33%           
Ertapenem 1 1             
  33.3% 100%             
Colistin                 
                  
Vancomycin                 
                  
Trimethoprim- 
Sulfamethoxazole           1     
            100%     
INH &             
Rifampicin                 
          Total       3 1 3 6 4 1 2 1 
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Table 3.20 Reported antibiotic sensitivity profiles of microorganisms (continuation of 
Table 3.19 above)    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
              
   
                                                         
ANTIBIOTICS - STRVI HAEPA MTB STRMI STRGF Total 
SENSITIVITY             
Penicillin/ 1    3 3 18 
Ampicillin 50%     75% 60%   
Ampicillin/  1     1 
Amoxicillin   100%         
Cloxacillin           2 
              
Piperacillin/           3 
Tazobactam             
Amoxicillin-           3 
Clavulanic acid             
Cefotaxime/ 1     1   8 
Ceftriaxone 
(3rd generation 
Cephalosporin) 50%     25%     
Ceftazidime           3 
(3rd generation 
Cephalosporin)             
Cefepime 
(4th generation           5 
Cephalosporin             
Erythromycin/           1 
Azithromycin             
Clindamycin         1 2 
          20%   
Ciprofloxacin           5 
              
Ertapenem           5 
              
Colistin           4 
              
Vancomycin         1 9 
          20%   
Trimethoprim- 
Sulfamethoxazole           1 
              
INH &    
1     
(100%)    1 
Rifampicin             
          Total 2 1 1 4 5 72 
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   Table 3.21 Reported antibiotic resistance profiles of microorganisms 
ANTIBIOTIC - STAHA STAEP ENTFA/ ACIBA KLE- STAAU CNS ENT- SERMA/ MOG- CITFR Total 
RESISTANCE     ENCFE   SP     CL SERSP MO     
Penicillin/ 1 1      1 
1 
       4 
Ampicillin                         
Ampicillin/    3  3    2 2 2 1 13 
Amoxicillin                         
Cloxacillin 2 1         1         4 
                          
Piperacillin/       8               8 
Tazobactam                         
Amoxicillin-         
1 
     2 1 2 1 7 
Clavulanic acid                         
Cefazolin         1         1   2 
(1st generation 
Cephalosporin)                         
Cefuroxime       1        1 2 
(2nd generation 
Cephalosporin)                    
Cefotaxime/         
1 
             1 
Ceftriaxone 
(3rd generation 
Cephalosporin)                         
Ceftazidime       
4 
 1           1 6 
(3rd generation 
Cephalosporin)                         
Cefepime 
(4th generation       6 1             7 
Cephalosporin)                         
Erythromycin/   1                   1 
Azithromycin                         
Clindamycin   1                   1 
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Trimethoprim-  1   4 1       1   7 
Sulfamethoxazole                    
Ciprofloxacin       
4 
               4 
                          
Imipenem       7               7 
                          
Meropenem       8               8 
                          
Tobramycin                 2                      2 
                          
Amikacin      1            1 
                          
Gentamicin 
    4      1  5 
          Total 3 5 3 48 10 1 2 4 3 7 4 90 
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For commonly isolated microbes with recorded incidences of sensitivity and 
resistance to a specific antibiotic, reported suggestions of directed  therapeutic usage 
of antibiotics could be used to infer correct empiric antibiotic usage 
recommendations, retrospectively. Although empiric antibiotic usage guidelines 
cannot be based on this study solely, the following inferences were made: 
 
Cefotaxime/Ceftriaxone ( third generation cephalosporins) are suitable alternatives to 
amoxicillin – clavulanic acid in treating patients with DNIs caused by Klebsiella  
(KLESP), as their susceptibility and resistance profiles are equivalent, 67% and 33% 
respectively. In practical terms, this is also a consideration when amoxicillin – 
clavulanic acid is out of stock, as occasionally does occur in resources stretched 
tertiary hospitals such as CHBAH. Penicillin/Ampicillin may be used in the treatment 
of patients with DNIs caused by Coagulase negative staphylococcocus (CNS), with a 
reported sensitivity of 67%. One reported case of CNS resistance to cloxacillin was 
noted. Ceftazidime (a third generation cephalosporin) and Ciprofloxacin should 
preferably not be used in the treatment of patients with DNIs caused by 
Acinetobacter baumannii (ACIBA), as antibiotic resistance patterns approaches that 
of 57% and 67%, respectively. Colistin is the reported antibiotic of choice in the 
treatment of patients with DNIs caused by ACIBA with multiple drug resistance.  
 
For microbes with recorded incidences of sensitivity to a specific antibiotic without 
recorded incidences of antibiotic resistance, a 100%  microbial antibiotic sensitivity 
was inferred. For microbes with recorded incidences of resistance to a specific 
antibiotic without recorded incidences of antibiotic sensitivity, a 100%  microbial 
antibiotic resistance was however, as a bias, not inferred in this study. This highlights 
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the need for standardisation of antibiotic susceptibility and resistance profile test 
batteries for commonly encountered microbes within a population such as those of 
this study. This would also aid surveillance for multi drug resistant microbes. 
 
It is, however, suggested from this study that the empiric antibiotics used as part of 
the management of adult patients with DNIs at CHBAH should idealistically include 
those that are effective against the most frequently isolated microorganisms, namely 
- Acinetobacter baumannii (ACIBA), Streptococcus pyogenes (STRPY),  
Streptococcus anginosus (STRAN),  Enterococcus faecalis / Enterococcus faecium 
(ENTFA/ENCFE); Coagulase negative staphylococcocus (CNS), Streptococcus 
Group F (STRGF), Streptococcus milleri (STRMI) and Klebsiella (KLESP); 
respectively.   
 
In practice, this may not be feasible: ACIBA accounted for 53% (n=48) of reported 
cases of antibiotic resistance, including multiple drug resistance and one cannot 
justify the use of colistin as a first line empiric antibiotic in patients presenting with 
DNIs, without evidence based practice guidelines. The reported number of cases of 
STRPY sensitivity to penicillin/ampicillin was 83% (n=5), and to clindamycin was 17% 
(n=1). Notably, one patient cultured STRPY as a polymicrobial isolate; one of three 
microorganisms -  with Staphylococcus haemolyticus (STAHA) being reported as 
resistant to penicillin/ampicillin and sensitive to vancomycin (Appendix 1B).  
                                                                     
Although empiric antibiotic usage recommendations cannot be based on case 
reports, principles of usage and associated clinical effectiveness should take into 
consideration polymicrobial patterns of growth of frequently isolated microbes.  
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The reported number of cases of STRAN sensitivity to penicillin/ampicillin was 100% 
(n=4). However, in 3 patients, Gram negative bacilli (GNB) and additionally in 1 of the 
above 3 patients,  Gram positive bacilli (GPB), were observed on microscopy and not 
identified on culture as polymicrobial isolates with Streptococcus anginosus (STRAN) 
(Appendix 1B ).   
 
The reported number of cases of Enterococcus faecalis / Enterococcus faecium 
(ENTFA/ENCFE) sensitivity to penicillin/ampicillin was 25% (n=1), and to vancomycin 
was 75% (n=3) with associated reported resistance to ampicillin/amoxicillin 
(Appendix 1B). For the one reported case of ENTFA sensitivity to penicillin/ampicillin, 
polymicrobial growth with Acinetobacter baumannii (ACIBA) reported as being 
resistant to piperacillin-tazobactam, carbapenems and cefepime, a fourth generation 
cephalosporin, was noted; thus negating the clinical significance of ENTFA sensitivity 
to penicillin/ampicillin. For the 3 reported cases of ENCFE sensitivity to vancomycin 
with associated ampicillin/amoxicillin resistance, polymicrobial growth patterns with 
Coagulase negative staphylococcocus (CNS); Staphylococcus epidermidis (STAEP) 
and an unidentified Bacillus species (BACSP); and Gram negative bacilli (GNB) on 
microscopy only, respectively; was also noted. Similarly, these other identified 
microorganisms in polymicrobial growth patterns with ENCFE, were reported as 
being vancomycin sensitive with associated resistance to penicillin/ampicillin, and 
ampicillin/amoxicillin amongst other antibiotics, respectively (Appendix 1B). 
 
 CNS and Streptococcus Group F (STRGF), isolated as single microorganisms, were 
reported as being penicillin/ampicillin sensitive. When isolated in a polymicrobial 
growth pattern with STRGF, anaerobic prevotella, and Gram positive bacilli (GPB) on 
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microscopy only, CNS and STRGF were both reported as being sensitive to 
penicillin/ampicillin and vancomycin. The reported number of cases of STRGF 
sensitivity to penicillin/ampicillin was 60% (n=3) and to clindamycin and vancomycin 
was 20% (n=1), respectively. Thus, in these instances, isolation of CNS and STRGF 
as single microorganisms or together in polymicrobial growth patterns, with or without 
unidentified GPB on microscopy, does not negate their individual sensitivities to 
penicillin/ampicillin.  
 
The reported number of cases of Streptococcus milleri (STRMI) sensitivity to 
penicillin/ampicillin was 75% (n=3) and to cefotaxime/ceftriaxone (3rd generation 
cephalosporins) was 25% (n=1), respectively.  Polymicrobial isolation of STRMI with 
unidentified gram negative bacilli (GNB), anaerobic prevotella and unidentified gram 
positive bacilli (GPB), was noted. However, no reported antibiotic susceptibility 
profiles for these other microorganisms were documented (Appendix 1B). Thus, the 
clinical relevance of STRMI sensitivity to penicillin/ampicillin and 
cefotaxime/ceftriaxone, in this context of polymicrobial isolation, cannot be inferred. 
                                                              
The reported number of cases of Klebsiella (KLESP) sensitivity to amoxicillin - 
clavulanic acid was 40% (n=2), to cefotaxime/ceftriaxone (3rd generation 
cephalosporins) was 40% (n=2) and to ertapenem was 20%, respectively. KLESP 
isolated as a single microorganism was sensitive to amoxicillin – clavulanic acid and 
cefotaxime/ceftriaxone with resistance to ampicillin/amoxicillin, in 2 reported cases. 
Extended spectrum beta lactamase producing Klebsiella (ESBL KLESP) isolated in a 
polymicrobial growth pattern with a multiple drug resistant Acinetobacter baumannii  
(ACIBA), and Streptococcus viridans (STRVI); was reported as being sensitive to 
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ertapenem with associated resistance to multiple antibiotics including amoxicillin – 
clavulanic acid and cefotaxime/ceftriaxone, nonetheless. Recommended antibiotic 
usage entailed escalated dual therapy consisting of a combination of colistin and 
ceftriaxone for the treatment of all 3 microorganisms (Appendix 1B). 
 
Polymicrobial growth patterns of commonly isolated microorganisms have proven to 
be incidentally random, unpredictable, complex occurrences; probably largely 
dependant on host and environmental factors Taking this into consideration when 
recommending empiric antibiotic usage guidelines, as part of the management of 
patients with DNIs, could possibly be a challenge of mammoth proportions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
47 
 
Table 3.22 An overview of reported number of cases of microbial antibiotic 
resistance  
 
 
The reported number of cases of microbial resistance to penicillins in general was 
40% (n=36) with an 8% (n=7) reported resistance to amoxicillin-clavulanic acid 
specifically. In descending order of frequency, the reported number of cases of  
   
Antibiotics No. of 
cases. 
Cephalosporins  
        1st  generation: Cefazolin 
         2nd generation: Cefuroxime  
         3rd generation: Ceftazidime, Cefotaxime / Ceftriaxone 
         4th  generation:Cefepime                                                                                                                              
18:- 
(2) 
(2) 
(7) 
(7)
Macrolides (Erythromycin / Azithromycin) 1 
Lincosamides  (Clindamycin) 1 
Sulphonamides (Trimethoprim – Sulphamethoxazole) 7 
Carbapenems ( Imipenem, Meropenem ) 15 
Aminoglycosides (Gentamycin, Tobramycin, Amikacin) 8 
Quinolones (Ciprofloxacin) 4 
Penicillins (Penicillin/Ampicillin; cloxacillin; Ampicillin/amoxicillin;  
Piperacillin / Tazobactam; Amoxicillin – Clavulanic acid.) 
36 
Glycopeptides (Vancomycin) 0 
Total 90 
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microbial resistance to penicillins was of the first order, followed by cephalosporins, 
third and fourth generations in particular, and carbapenems, respectively. 
 
3.3.1 Profiles of microbial susceptibility and resistance to amoxicillin – 
clavulanic acid 
 
Microbial sensitivity to amoxicillin – clavulanic acid was reported in only 3 of the 52 
patients (6%) and that of microbial resistance in only 5 patients (10%) of the total 
study population.  
 
3.3.1.1 Profile of microbial susceptibility to amoxicillin – clavulanic acid 
1.     
Code 
no. 
         
Aerobic 
Anaerobic Other 
Antibiotic 
(Sensitivity) 
Antibiotic 
(Resistance) 
29 Klebsiella _ _ 
amoxicillin-
clavulanic acid; 
cefotaxime/ 
ceftriaxone 
Ampicillin/ amoxicillin 
30 
_ENTFA  
_ACIBA 
_ _ 
_ Penicillin/ 
ampicillin 
_Ceftazidime 
_                                                                                              
_piperacillin-
tazobactam; cefepime; 
imipenem; meropenem     
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2. 
Code 
no. 
         
Aerobic 
Anaerobic Other 
Antibiotic 
(Sensitivity) 
Antibiotic (Resistance) 
42 KLESP _ _ 
amoxicillin-
clavulanic   
acid; 
cefotaxime/ 
ceftriaxone                              
Ampicillin/ amoxicillin 
43 ACIBA _ _ Colistin 
_piperacillin/ tazobactam; 
ciprofloxacin; ceftazidime; 
cefepime; gentamicin; 
imipenem; meropenem  
44 ACIBA _ _ Colistin 
 _piperacillin/ tazobactam; 
trimethoprim-
sulfamethoxazole; 
ciprofloxacin; ceftazidime; 
cefepime; gentamicin; 
tobramycin; imipenem; 
meropenem               
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3. 
Code 
no. 
         Aerobic Anaerobic Other 
Antibiotic 
(Sensitivity) 
Antibiotic 
(Resistance) 
49 ESCCO _ _ 
amoxicillin-
clavulanic acid                                 
_ 
 
Klebsiella (KLESP) and Escherichia coli (ESCCO), both gram negative bacilli (GNB), 
were the only two of twenty six identified microbes (8%) in this study with reported 
sensitivity to amoxicillin – clavulanic acid; 3 of 57 microbes (5%) when all pathogens 
were considered. KLESP, isolated in polymicrobial growth patterns with 
Acinetobacter baumannii (ACIBA) in particular, offset the significance of its sensitivity 
to amoxicillin – clavulanic acid, with third generation cephalosporins and polymyxins 
suggested as alternative or combination antimicrobial management options 
respectively.  
 
In the context of polymicrobial growth patterns with KLESP, ACIBA was reported as 
conferring resistance to multiple drugs. Specific testing and reporting of ACIBA 
susceptibility to amoxicillin – clavulanic acid, however, was not documented in this 
study population. ESCCO was isolated in a monomicrobial, as opposed to 
polymicrobial, growth pattern, thus its antimicrobial sensitivity pattern was not 
clinically negated. 
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3.3.1.2 Profile of microbial resistance to amoxicillin – clavulanic acid 
 
 1. 
Code 
no. 
    Aerobic Anaerobic Other 
Antibiotic 
(Sensitivity) 
Antibiotic  
(Resistance) 
56 
_ACIBA 
_ _ 
_colistin                   
_ertapenem              
_cefotaxime/ 
ceftriaxone 
(colistin & 
ceftriaxone  
combination for 
all 3 
microorganisms)  
_trimethoprim-
sulfamethoxazole; 
ciprofloxacin; ceftazidime; 
cefepime; gentamicin 
piperacillin/ tazobactam; 
imipenem; meropenem 
_ ESBL 
KLESP 
_STRVI 
_ trimethoprim-
sulfamethoxazole;ampicillin/ 
amoxicillin; amoxicillin-
clavulanic acid;cefazolin; 
cefuroxime; cefotaxime/ 
ceftriaxone; ceftazidime; 
cefepime        
 _ 
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2. 
Code 
no. 
    Aerobic Anaerobic Other 
Antibiotic 
(Sensitivity) 
Antibiotic  
(Resistance) 
59 
_SERSP                     
_ENTCL 
_ _ 
_piperacillin/ 
tazobactam 
cefepime              
_piperacillin/ 
tazobactam; 
cefepime 
_ampicllin/ 
amoxicillin                             
_ amoxicillin-
clavulanic 
acid;ampicillin/ 
amoxicillin 
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3. 
Code 
no. 
    Aerobic Anaerobic Other 
Antibiotic 
(Sensitivity) 
Antibiotic  
(Resistance) 
61 STRAN _ 
GPB 
1+ 
GNB 
3+ 
Penicillin _ 
62 
_ENTCL 
_ _ 
_ciprofloxacin; cefepime; 
ertapenem 
_ciprofloxacin           
_ciprofloxacin; cefepime; 
ertapenem 
                                                 
_amoxicillin-
clavulanic 
acid;ampicillin/ 
amoxicillin                                
_piperacillin/ 
tazobactam; 
trimethoprim-
sulfamethoxazole; 
meropenem                         
_amoxicillin-
clavulanic 
acid;ampicillin/ 
amoxicillin 
_ACIBA             
_SERMA 
63 ACIBA _ _ Ciprofloxacin;ceftazidime 
Piperacillin/ 
tazobactam ;  
meropenem; 
imipenem 
54 
 
 
4. 
Code 
no. 
    Aerobic Anaerobic Other 
Antibiotic 
(Sensitivity) 
Antibiotic  
(Resistance) 
66 _ _ 
GPC 
3+ 
_ _ 
67 
                          
_CITFR                
_ACIBA  
_ _ 
_Ertapenem            
_Ceftazidime 
_amoxicillin-clavulanic 
acid;ampicillin/ 
amoxicillin;cefuroxime; 
ceftazidime                                                                   
_piperacillin/ 
tazobactam ; 
meropenem;cefepime; 
imipenem    
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5. 
Code 
no. 
    Aerobic Anaerobic Other 
Antibiotic 
(Sensitivity) 
Antibiotic  
(Resistance) 
69 MOGMO _ 
GPC 3+ 
(lost 
viability) 
Ertapenem; 
cefepime 
amoxicillin-clavulanic 
acid; trimethoprim-
sulfamethoxazole; 
ampicillin/ amoxicillin; 
cefazolin; gentamicin 
70 MOGMO _ 
GPC 3+ 
(lost 
viability) 
piperacillin/ 
tazobactam 
amoxicillin-clavulanic 
acid;ampicillin/amoxicillin                                 
 
 
Extended spectrum beta lactamase producing Klebsiella (ESBL KLESP), 
Enterobacter cloacae (ENTCL), Serratia marcescens (SERMA), Citrobacter freundii 
(CITFR) and Morganella morganii (MOGMO), interestingly all gram negative bacilli 
(GNB), were the 5 of 26 identified microbes (19%) in this study with reported 
resistance to amoxicillin – clavulanic acid, 7 of 57 microbes (12%) when all 
pathogens were considered. 
 
 Recommended alternative antimicrobial coverage included: Ertapenem effective 
against MOGMO, CITFR, ENTCL, SERMA and ESBL KLESP; cefepime effective  
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against MOGMO, ENTCL and SERMA ; piperacillin – tazobactam effective against 
MOGMO and ENTCL and Ciprofloxacin was effective against ENTCL and SERMA. 
 
ESBL KLESP, isolated in a polymicrobial growth pattern with Acinetobacter 
baumannii (ACIBA) in particular, was reported as being resistant to amoxicillin – 
clavulanic acid, with  third generation cephalosporins and polymyxins suggested as 
an alternative combination antimicrobial management option.  This highlights the 
significance of polymicrobial growth patterns when selecting empiric antimicrobial 
agents in the management of DNIs. Further research is required to determine if there 
is a need to define criteria for escalating empiric antibiotic therapy to include 
combination antimicrobial options in the context of polymicrobial growth patterns, 
emphasizing co – existing gram negative bacilli (GNB), in DNIs. 
 
 Further, Enterobacter cloacae (ENTCL), isolated in a polymicrobial growth pattern 
with Serratia species (SERSP),  was reported as being resistant to amoxicillin – 
clavulanic acid; with another B lactamase resistant penicillin, namely 
piperacillin/tazobactam, or a fourth generation cephalosporin, suggested as an 
alternative. Both these co – existing GNB displayed antimicrobial susceptibility to the 
same antimicrobial agents. However, when these two microbial species were isolated 
in a polymicrobial growth pattern together with Acinetobacter baumannii (ACIBA), 
both still displayed resistance to amoxicillin – clavulanic acid, however the alternative 
antimicrobial agent of choice in this instance, was a fluoroquinolone, namely 
ciprofloxacin.  
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Yet when Citrobacter freundii (CITFR) was isolated in a polymicrobial growth pattern 
with ACIBA, CITFR was resistant to amoxicillin – clavulanic acid, however both 
microbes displayed differing antimicrobial susceptibility profiles, and a combination of 
a third generation cephalosporin, namely ceftazidime, and a carbapenem, 
ertapenem, was suggested as appropriate alternative antimicrobial agents. 
Morganella morganii (MOGMO), isolated in a monomicrobial growth pattern, was 
susceptible to multiple antibiotic classes, including other beta -  lactamase resistant 
penicillins, carbapenems and fourth generation cephalosporins, as alternatives to 
amoxicillin – clavulanic acid.  
 
Table 3.23 Amoxicillin – clavulanic acid sensitivity trend for microorganisms  
Year No.      Duration KLESP ESCCO 
1 07/2008-06/2009 _ _ 
2 07/2009-06/2010 _ _ 
3 07/2010-06/2011 _ _ 
4 07/2011-06/2012 _ _ 
5 07/2012-06/2013 1 (100%) _ 
6 07/2013-06/2014 1 (100%) _ 
7 07/2014-06/2015 _ 1 (100%) 
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Table 3.24 Amoxicillin – clavulanic acid resistance trend for microorganisms 
Year No.      Duration KLESP ENTCL SERMA CITFR MOGMO 
1 07/2008-06/2009 _ _ _ _ _ 
2 07/2009-06/2010 _ _ _ _ _ 
3 07/2010-06/2011 _ _ _ _ _ 
4 07/2011-06/2012 _ _ _ _ _ 
5 07/2012-06/2013 _ _ _ _ _ 
6 07/2013-06/2014 _ _ _ _ _ 
7 07/2014-06/2015 1  2  1  1  2  
 
The reported sensitivity trend of microorganisms – specifically Klebsiella (KLESP) 
and Escherichia coli (ESCCO) - to amoxicillin – clavulanic acid has been fairly 
consistent over the seven year study period, with per annual, 100% sensitivity 
inferred.  Extended spectrum beta lactamase producing Klebsiella (ESBL KLESP), 
Enterobacter cloacae (ENTCL), Serratia marcescens (SERMA), Citrobacter freundii 
(CITFR) and Morganella morganii (MOGMO), were the 5 of 26 identified microbial                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
subtypes (19%), resistant to amoxicillin – clavulanic acid, 7 of 57 microbes (12%), 
when all microorganisms were considered. These microorganisms were all reported 
as being resistant to amoxicillin – clavulanic acid, specifically over the final year of 
the study period, 07/2014 – 06/2015, with slightly higher incidences reported in 
ENTCL and MOGMO.  
 
In contrast, no such resistance to amoxicillin – clavulanic acid in any microorganism 
regardless, was reported over the entire initial 6 years of the study period, 07/2008 – 
06/2014. Neither, was there a comparative reported amoxicillin – clavulanic acid 
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sensitivity profile recorded for the above 5 microorganisms, in the final year of the 
study. Notably concerning was the ratio of reported amoxicillin – clavulanic acid 
resistance : sensitivity of 7:1 in the final year of the study; and that this antimicrobial 
resistance profile was specific to the above mentioned identified gram negative bacilli 
(GNB) on patient specimen cultures. These micro – organisms were not amongst 
those most frequently isolated and identified in adult patients with DNIs at CHBAH. 
  
It is however emphasized that profiles of microbial sensitivity and resistance to 
amoxicillin – clavulanic acid was reported in only 15% ( n = 8) of patients with DNIs. 
Thus, the significance of this reported increased resistance to amoxicillin – clavulanic 
acid cannot be ascertained due to the small numbers of the study population tested. 
Furthermore, recommendations for, nor against the continuing use of amoxicillin – 
clavulanic acid, as the empiric antibiotic of choice, as part of the management of 
patients with DNIs, cannot be made based on this study.  
                                                                
In this study, when microbial resistance to amoxicillin – clavulanic acid was 
encountered, suggested alternative antimicrobial agents included third or fourth 
generation cephalosporins, polymyxins or carbapenems ; either as single agents or 
as combination therapy. Flouroquinolones and other beta – lactamase resistant 
penicillins were also favoured alternatives. Recommended alternative antimicrobial 
coverage, in patients with reported resistance to amoxicillin – clavulanic acid, 
included: Ertapenem effective against Morganella morganii (MOGMO), Citrobacter 
freundii (CITFR), Enterobacter cloacae (ENTCL), Serratia marcescens (SERMA) and 
extended spectrum beta lactamase producing Klebsiella (ESBL KLESP); cefepime 
effective against MOGMO, ENTCL and SERMA; piperacillin – tazobactam effective 
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against MOGMO and ENTCL and Ciprofloxacin was effective against ENTCL and 
SERMA (Appendix IB). 
  
In a study of 101 patients with deep neck abscesses, amoxicillin - clavulanic acid was 
used empirically in 82.1% of cases and was based on the coverage of bacteria 
commonly found in their environment; other recommendations included cefuroxime, 
meropenem or imipenem; in combination with an antibiotic, which is highly effective 
against most anaerobes (such as metronidazole or clindamycin).31 This 
recommendation for the usage of clindamycin is not in keeping with other literature; 
this study of 365 patients stated that the most frequently provided treatment 
regimens, alone or in combination, were amoxicillin - clavulanic acid (59%), second 
and third generation cephalosporins (37%), ampicillin – sulbactam (13%), 
clindamycin (11%), metronidazole (4%) and vancomycin (2%).1 
                            
In this study, when all micro-organisms were considered, only 7% (n=4) were isolated 
and identified anaerobes; there was no routine reporting on antibiotic susceptibility of 
identified anaerobes, although metronidazole was suggested for the treatment of 
prevotella (Appendix 1B). Staphylococcus epidermidis (STAEP) resistance to 
clindamycin was reported in 1% of cases. Streptococcus pyogenes  (STRPY) and 
Streptococcus Group F (STRGF) sensitivity to clindamycin was reported in 1% of 
cases, respectively. Routine surveillance of endemic microorganisms and antibiotic 
susceptibility trends is emphasised.  
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3.4 Analysis of Histology Distribution 
 
A total of ten patients who had more than one specimen MC&S result per surgical 
procedure for DNI, did not have additional specimen histological analysis done, and 
were thus depicted with “ - “  in Appendix IA. This was also depicted for the one 
rejected MC&S specimen in Appendix IA.  
 
Table 3.25 Histology distribution: Categorisation of patients’ specimen results 
Result 
category 
No. of 
patient 
specimens 
% 
Histology 17 29 
No Results 39 67 
Rejected 2 4 
Total 58 100 
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Histology Distribution
29%
67%
4%
Histology
No results
Rejected
 
Figure 3.7 Histology distribution: Categorisation of patients’ specimen results 
 
A histological analysis was done on 29% (n=17) of patient specimens. For 67% 
(n=39) of patient specimens, no results were found and for 4% (n=2) of patient 
specimens, histology results were rejected. The Student’s t-test for age and gender  
distribution per histology distribution, revealed a significant difference (p<0.05) 
between the mean ages of male and female patients, respectively. 
 
3.4.1 Analysis of tissue necrosis distribution 
Table 3.26 Tissue necrosis distribution: Categorisation of patients’ specimen results 
Result 
category 
No. of 
patient 
specimens          % 
Positive 15 88% 
Negative 2 12% 
Total 17 100 
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Tissue Necrosis Distribution
88%
12%
Positive
Negative
 
 Figure 3.8 Tissue necrosis distribution: Categorisation of patients’ specimen results 
                                                           
Tissue necrosis was evident in 88% (n=15) of patients’ histological specimens and in 
12% (n=2), no tissue necrosis was found. The Student’s t-test for age and gender 
distribution per tissue necrosis distribution, respectively; revealed a significant 
difference (p<0.05).  
 
3.5 Microbiology of DNI and Pulmonary and Extra - Pulmonary Tuberculosis:  
      Case Reports 
 
Key global priorities for tuberculosis (TB) care and control include improving case-
detection and detecting cases earlier, including cases of smear-negative disease 
which are often associated with co-infection with the human immunodeficiency virus 
(HIV) and with young age. In 2014, an estimated 1.2 million (13%) of the 9.6 million 
people who developed TB worldwide were HIV-positive. The African Region 
accounted for 73% of the estimated number of HIV-positive incident TB cases.29 
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1.               
 
 
 
 
 
 
 
Code 
no. 
         Aerobic Anaerobic Other 
Antibiotic 
(Sensitivity) 
Antibiotic 
(Resistance) 
38 _ _ _ _ _ 
 
A 42 year old male, retroviral disease positive on anti – retroviral therapy. He had a 
clinical history of pulmonary TB supported by a miliary TB pattern on pulmonary CT 
imaging. He presented with a 10 day history of a DNI involving the supraclavicular 
region, with signs of superimposed acute inflammation. His DNI specimen MC&S 
result showed no microbial growth; kinyoun stain was negative for acid fast bacilli. 
There was no record of initiation of empiric anti-TB therapy. The patient was lost to 
follow up. 
 
2.                
 
 
 
 
 
 
Code 
no. 
         Aerobic Anaerobic Other 
Antibiotic 
(Sensitivity) 
Antibiotic 
(Resistance) 
26 
AFB&MTB (on 
PCR) 
_ _  INH/rifampicin _ 
27 _ _ _ _ _ 
  
 
 
 
Code 
No. 
 
Date of 
Surgery 
 
Gender 
(M/F) 
Age 
(years) 
Bacterial 
Growth 
(Y/N) 
Histology 
  
(Y/N) 
Tissue 
Necrosis 
(Y/N) 
38 2013/10/26 M 42 N N _ 
Code 
No. 
 
Date of 
Surgery 
 
Gender 
(M/F) 
Age 
(years) 
Bacterial 
Growth 
(Y/N) 
Histology 
  
(Y/N) 
Tissue 
Necrosis 
(Y/N) 
26 2012/12/23 M 36 Y N _ 
27 2012/12/23 M 36 N _ _ 
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A 36 year old male, retroviral disease positive, CD4 < 350 and not on anti – retroviral 
therapy. He presented with multiple, bilateral necrotic cervical lymphadenopathy with 
retropharyngeal abscess formation on CT (duration of associated clinical symptoms 
of > 1 month). A neck incision & drainage was done for pressure relief on the airway. 
Intraoperatively, caseous material was drained, thus empiric anti TB treatment was 
initiated post operatively. His DNI specimen MC&S result showed no microbial 
growth. Microscopy (fluorochrome method) was negative for acid fast bacilli. Culture 
was, however, positive for AFB after 14 days incubation. PCR on culture was positive 
for MTB complex which was INH & Rifampicin susceptible. Sputum TB microscopy 
(auramine stain) was smear positive for AFB. 
 
3.            
 
 
 
 
 
Code 
no. 
         Aerobic Anaerobic Other 
Antibiotic 
(Sensitivity) 
Antibiotic 
(Resistance) 
6 _ _ _ _ _ 
 
A 29 year old female, retroviral disease positive (AIDS), CD4 159, not on anti – 
retroviral therapy. She presented with a history of a right submandibular abscess of 6 
months duration with signs of superimposed acute inflammation.   
 
 
 
 
Code 
No. 
 
Date of 
Surgery 
 
Gender 
(M/F) 
Age 
(years) 
Bacterial 
Growth 
(Y/N) 
Histology 
  
(Y/N) 
Tissue 
Necrosis 
(Y/N) 
6 2009/02/26 F 29 N N _ 
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Pulmonary TB was diagnosed (smear positive for AFB) and anti – TB treatment was 
initiated 1 day prior to incision & drainage of DNI. DNI specimen MC&S result 
(2009/02/26) showed no microbial growth. DNI specimen TB investigation was not 
recorded on the NHLS data system. On retrospective review, the patient was smear 
positive for AFB on sputum specimen (11/07/2010) & positive for AFB on blood 
culture (08/07/2010) after 40 days incubation, despite being on re - treatment for 
pulmonary TB since May 2010. There was no record on the NHLS data system 
regarding exclusion of multi drug resistant TB. The patient was diagnosed with AIDS, 
CD4 174, on anti – retroviral therapy (11/07/2010). She subsequently demised on 
22/07/2010. 
 
4.                
 
 
 
 
 
Code 
no. 
         Aerobic Anaerobic Other 
Antibiotic 
(Sensitivity) 
Antibiotic 
(Resistance) 
1 
CANAL 
(subculture) 
_ 
GPC 
+ 
_ _ 
 
 
A 21 year old female, retroviral disease positive, CD4 157, not on anti – retroviral 
therapy. She presented with multiple neck abscesses on CT, predominantly involving 
the left parapharyngeal space extending to levels III & IV clinically, of two months 
duration with superimposed signs of acute inflammation. Empiric anti TB treatment 
was initiated (10/07/2008). 
 
Code 
No. 
 
Date of 
Surgery 
 
Gender 
(M/F) 
Age 
(years) 
Bacterial 
Growth 
(Y/N) 
Histology 
  
(Y/N) 
Tissue 
Necrosis 
(Y/N) 
1 2008/07/21 F 21 Y N (PNS) _ 
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Incision & drainage of DNI (21/07/2008) was done. DNI specimen MC&S result 
(26/02/2009) showed Candida albicans (CANAL) on subculture & gram positive cocci 
(GPC) on microscopy only. Intra – operative DNI specimen TB investigation results 
were not recorded on the NHLS data system.  
 
Although pre operative DNI specimen MC&S results were excluded, pre operative 
DNI aspirate specimen TB investigation results (09/07/08) deserves mention in 
retrospect: Microscopy was negative for AFB. Culture was positive for AFB after 17 
days incubation. Antibiotic susceptibility results showed rifampicin & ethambutol 
sensitivity; isoniazid & streptomycin resistance.  
 
Of note, a second pre operative DNI aspirate specimen was submitted for TB 
investigation  (09/07/08): Microscopy was negative for AFB. Culture was negative for 
AFB after 42 days incubation. However, histology of an adenoidal - like post nasal 
space mass biopsy taken in theatre confirmed mycobacterial infection (necrotizing 
granulomatous inflammation, positive for AFB on Ziehl Neelsen stain).                                                          
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Table 3.27 TB investigations in DNIs 
 
Table 3.28 TB investigations in DNIs: Histology & staining 
 
 
 
Notably, peri – operative DNI specimens/aspirates sent for TB investigations, were 
commented on. There were 5 specimens sent for TB cultures which were 
contaminated, another specimen was reincubated, however, no result was found. 
There were 2 specimens not processed due to laboratory errors. TB microscopy was 
done using the kinyoun, flouorochrome and auramine o staining techniques. TB 
culture results were reported after a minimum of 29 days and on average after 42 
days of incubation. 
 
In patients with extrapulmonary TB DNIs  suggested clinically and or radiologically;  
no growth was observed on culture in 75%, no AFBs detected on microscopy in 50%; 
AFB positive on culture and mycobacterium complex detected on PCR in 25%. 
TB 
Investigation 
Positive 
(%) 
Negative 
(%) 
Total (%) 
Microscopy 0 (0 %) 54  (72%) 54  (70%) 
Culture 1 (50%) 21 (28%) 22  (29%) 
PCR 1 (50%) 0   (0%)   1  (1%) 
Total 2 (100%) 75 (100%) 77 (100%) 
TB Histology & 
staining 
Positive 
(%) 
Negative 
(%) 
Total (%) 
ZN stain 0 (0%) 13 (48%) 13 (48%) 
Granulomatous 
inflammation 
0 (0%) 14 (52%) 14 (52%) 
Total 0 (0%) 27 (100%) 27 (100%) 
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Therapeutic and empiric anti-TB therapy was initiated in 25% and 50% of patients, 
respectively. 
 
Pulmonary & extrapulmonary TB could represent sources of TB DNI; or in addition to 
retroviral disease, it could represent an underlying immune – compromising state that 
predisposes the host to other opportunistic coexisting microbial DNIs.  Although 
controversial, one extrapulmonary source of cervical tuberculous lymphadenopathy, 
is the tonsillar crypts; with lymphadenopathy occurring 6 to 9 months therafter. 
Similarly, in this study, the adenoids were cited as a probable source of TB DNI. 
There is also a reported association between tuberculous lymphadenitis and HIV 
infection; thereby facilitating early haematogenous dissemination to single or multiple 
non – pulmonary sites.30  
 
Extrapolations and commonalities amongst  patients with suspected or confirmed TB 
DNIs, in this study, included : Relatively young ages of presentation, an average of 
32 years of age. Retroviral disease positivity, relatively low CD4 counts, with patients 
predominantly not on ARV’s. There were associated confirmed microbiological or 
radiological evidence of pulmonary TB; one exception being an extrapulmonary site 
(post nasal space), other than TB DNI. Presentations included prolonged duration of 
symptoms in suspected TB DNI, ranging from 10 days to 6 months and randomised 
sites of deep neck space involvement.  
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Primary indication for surgical intervention in suspected TB DNI included 
superimposed signs of acute inflammation; one exception being that for relief of 
airway pressure. 
 
DNI specimen MC&S results were reported predominantly as “no growth”, one 
exception being fungal growth on subculture with gram positive cocci (GPC) on 
microscopy. Thus, taking into consideration the clinical and radiological findings in 
patients with suspected TB DNI, MC&S reports of “no growth” should prompt further 
investigations for other opportunistic infections, eg. mycobacterial and fungal 
infections, particularly in young, retroviral disease positive patients with low CD4 
counts who are notably ARV therapy naive. 
 
The diagnostic yield of TB investigation in DNI relative to other extrapulmonary & 
pulmonary sites of infection, is inferred to be lower. Submitting greater than one 
specimen for TB investigation in TB DNI increases the probability of positive 
diagnostic yield.  Microscopy provided a null diagnostic yield in TB DNI relative to 
pulmonary & other extrapulmonary sites eg. post nasal space. In contrast, TB culture, 
PCR and histology revealed positive diagnostic yields, with a turnover time to positive 
culture ranging from 14 to 40 days. 
 
Given the high percentage of negative TB investigation results relative to confirmed 
TB in DNIs, it is inferred that routine TB investigations in DNIs, not be requested, 
unless clinically, radiologically or intra operatively suspected. However, low sensitivity 
& specificity rates for these TB investigation methods in DNI, cannot be excluded.  
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WHO’s policy recommendations state that lateral flow urine lipoarabinomannan 
assay (LF-LAM) may be used to assist in the diagnosis of TB in HIV positive adult in-
patients with signs and symptoms of TB (pulmonary and/or extrapulmonary) who 
have a CD4 cell count less than or equal to 100 cells/μL, or HIV positive patients who 
are seriously ill ( respiratory rate > 30/min, temperature > 39°C, heart rate > 120/min 
and unable to walk unaided )  regardless of CD4 count or with unknown CD4 count 
(conditional recommendation; low quality of evidence).  LF-LAM is easy to perform, 
requires minimal biosafety requirements, is inexpensive and allows for rapid 
diagnosis within approximately 25 minutes, thus facilitating the early initiation of anti-
TB treatment and reducing mortality in this patient group.29 
  
Empiric anti – TB treatment was initiated in two patients with DNI, in this study: 
- Indications included clinical and or radiological features with or without intra 
operative findings suggestive of TB DNI, particularly in retroviral disease 
positive patients. 
- Notably, one case of resistance to 2 anti TB drugs, namely, isoniazid and 
streptomycin, was reported on a preoperative DNI aspirated specimen 
antimicrobial sensitivity testing. 
   
There were 4 of 52 patients (8%) with suspected or confirmed TB DNI. This 
percentage of patients could possibly be an underscore of the actual number of 
patients with TB DNI at CHBAH. This represents a bias in the study method in that 
only patients with DNI treated surgically were considered; whilst TB DNI is a disease 
entity primarily managed medically. Nevertheless, it is inferred from this study that TB 
DNI is relatively uncommon; in keeping with the literature.23 However, in the context 
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of suspected TB DNI, the indications and recommended empiric antimicrobial agents 
of choice need to be clarified, to prevent the development of MDR TB and associated 
morbidity & mortality repercussions. 
 
3.6 Fungal DNI 
 
In 4% of patients, fungal DNIs was confirmed on subculture and histology in 50% of 
these patients, respectively. 
 
Table 3.29 Fungal investigations in DNIs 
 
Fungal 
investigation 
Positive (%) Negative (%) Total (%) 
Microscopy 0 (0%) 1 ( 0.1%) 1  ( 6%) 
Culture 1 (subculture)(50%) 2 (14%) 3  (19%) 
Histology: 
ABPAS/PAS 
staining          
1 (50%) 11(79%) 12 (75%) 
Total 2 (100%) 14 (100%) 16 (100%) 
 
It is inferred that fungal DNIs are relatively uncommon as well.  
 
3.7 Microbial MC&S and Related Morbidity and Mortality of Patients with DNIs 
 
For each patient with DNI who demised, data tables were extracted from appendix 
1A and 1B, respectively. Details related to the number of surgical procedures, 
specimen MC&S results, source of DNI, duration of hospital admission and most 
likely cause of death, were reviewed:  
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1.  
 
 
 
 
 
 
Code 
no. 
           
Aerobic 
Anaerobic Other 
Antibiotic 
(Sensitivity) 
Antibiotic (Resistance) 
47 
  
_  
                                           
_vancomycin   
_vancomycin  
_ampicillin/ amoxicillin    _Penicillin/ 
ampicillin; cloxacillin; erythromycin/ 
azithromycin; clindamycin; 
trimethoprim-sulfamethoxazole  
_ENCFE 
_STAEP  
_ BACSP 
(light 
growth)                  
48 CORSP CORSP _ _ _ 
 
Code No. 
 
Date of 
Surgery 
 
Gender 
(M/F) 
Age 
(years) 
 Bacterial 
Growth (Y/N) 
Histology 
  
(Y/N) 
Tissue 
Necrosis 
(Y/N) 
47 2014/08/14 F  7
4 
Y N _ 
48 2014/08/19 F  7
4 
Y N _ 
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The patient had an initial surgical procedure (14/8/2014) & one relook (19/8/2014). 
She had a polymicrobial aerobic and anaerobic growth pattern; [Enterococcus 
faecium (ENCFE), Staphylococcus epidermidis (STAEP), Corynebacterium species 
(CORSP) & an unidentified Bacillus species (BACSP)], identified as one of four 
pathogens per patient. There was no reported resistance to amoxicillin – clavulanic 
acid; reported vancomycin sensitivity. Directed antibiotic usage was not commenced 
due to clinical improvement post surgical drainage of DNI. The source of DNI was 
odontogenic. The duration of hospital admission was 12/8/2014 – 17/10/2014 
(prolonged hospital admission). The most likely cause of death was comorbidity 
related - DCMO with ejection fraction of 20% and persistent hypotension.  
 
2.  
Code 
No. 
 
 Date of 
Surgery 
 
Gender 
(M/F) 
Age 
(years) 
Bacterial 
Growth 
(Y/N) 
Histology 
  
(Y/N) 
Tissue 
Necrosis 
(Y/N) 
 51 2014/09/13 F 42 N Y N 
 
Code 
no. 
       Aerobic Anaerobic Other Antibiotic(Sensitivity) 
Antibiotic 
(Resistance) 
51 _ _ 
GPC 
2+ 
GNB 
2+ 
_ _ 
 
The patient had an initial surgical procedure (13/09/2014). 
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No microbial growth was identified on culture. Unidentified gram positive cocci (GPC) 
and gram negative bacilli (GNB) were isolated on microscopy only. Thus no microbial 
antibiotic susceptibility testing was done. The source of DNI was most likely 
odontogenic. Notably, CT features were suggestive of pulmonary TB. The histology 
of DNI showed no granulomata; modified Ziehl  Neelsen stain was negative for AFB. 
The duration of hospital admission was 13/09/2014 – 14/09/2014. The most likely  
cause of death was septic shock with a metabolic acidosis and acute kidney injury. 
 
3.  
Code 
No. 
 
Date of 
Surgery 
Gender 
(M/F) 
Age 
(years) 
Bacterial 
Growth 
(Y/N) 
Histology 
  
(Y/N) 
Tissue 
Necrosis 
(Y/N) 
 24 2012/07/31 M 30 Y N _ 
 
Code 
no. 
Aerobic Anaerobic Other Antibiotic(Sensitivity) 
Antibiotic 
(Resistance) 
24 STAAU _ _ Cloxacillin _ 
 
The patient had an initial surgical procedure (31/07/2012). Monomicrobial aerobic 
growth of Staphylococcus aureus (STAAU) was identified. There was no reported 
resistance to amoxicillin – clavulanic acid; reported cloxacillin sensitivity. The source 
of DNI was idiopathic. Notably, this patient was newly diagnosed retroviral disease 
positive, CD4 171; antiretroviral therapy was initiated during this admission. 
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The duration of hospital admission was 31/07/2012 – 19/09/2012 (prolonged hospital 
admission, with withdrawal of intensive care unit management secondary to poor 
prognosis). The most likely cause of death was sepsis related acute on chronic 
kidney disease and most likely ischaemic brain injury post cardiac arrest and 
resuscitation. 
 
4.  
 
 
 
 
Code 
no. 
Aerobic Anaerobic Other Antibiotic(Sensitivity) 
Antibiotic 
(Resistance) 
52 ENCFE _ 
G–B 
2+ 
Vancomycin Ampicillin/ amoxicillin 
 
The patient had an initial surgical procedure (29/09/2014). Monomicrobial aerobic 
growth [Enterococcus faecium (ENCFE)] was identified on culture with unidentified 
gram negative bacilli (GNB) isolated on microscopy only. Histology confirmed 
necrotising fasciitis. There was no reported resistance to amoxicillin – clavulanic acid; 
reported vancomycin sensitivity. The source of DNI was odontogenic. The duration of 
hospital admission was 29/09/2014 – 30/09/2014. The most likely cause of death 
was septic shock. The patient demised prior to obtaining microbial MC&S results and 
thus directed antibiotic usage was never commenced. 
 
 
 
Code 
no. 
Date of 
Surgery 
Gender 
(M/F) 
Age 
(years) 
Bacterial 
Growth 
(Y/N) 
Histology 
  
(Y/N) 
Tissue 
Necrosis 
(Y/N) 
52 2014/09/29 M 42 Y Y Y 
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5.  
Code 
no. 
Date of 
Surgery 
Gender 
(M/F) 
Age 
(years) 
Bacterial 
Growth 
(Y/N) 
Histology 
  
(Y/N) 
Tissue 
Necrosis 
(Y/N) 
42 2014/03/27 M 61 Y Y Y 
43 2014/03/27 M 61 Y _ _ 
44 2014/03/29 M 61 Y N _ 
 
Code 
no. 
Aerobic Anaerobic Other Antibiotic(Sensitivity) 
Antibiotic 
(Resistance) 
42 KLESP _ _ 
amoxicillin-clavulanic   
acid; cefotaxime/ 
ceftriaxone                              
Ampicillin/ amoxicillin 
43 ACIBA _ _ Colistin 
_piperacillin/ 
tazobactam; 
ciprofloxacin; 
ceftazidime; cefepime; 
gentamicin; imipenem; 
meropenem  
44 ACIBA _ _ Colistin 
 _piperacillin/ 
tazobactam; 
trimethoprim-
sulfamethoxazole; 
ciprofloxacin; 
ceftazidime; cefepime; 
gentamicin; 
tobramycin; imipenem; 
meropenem                    
 
The patient had an initial surgical procedure (27/03/2014) and one relook surgical 
procedure (29/03/2014). 
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There was polymicrobial aerobic growth [ Klebsiella (KLESP), Acinetobacter 
baumannii (ACIBA)], identified as one of 2 pathogens per patient. Histology 
confirmed necrotising fasciitis. There was no reported resistance to amoxicillin – 
clavulanic acid; reported colistin sensitivity. In the context of multi drug resistance, 
specific testing of microbial susceptibility to the current empiric antibiotic of choice,  
amoxicillin – clavulanic  acid, is recommended as part of the management of all adult 
patients with DNI. The source of DNI was odontogenic. The duration of hospital 
admission was 27/03/2014 – 30/03/2014. The most likely cause of death was sepsis 
related acute kidney injury (AKI). The patient demised prior to obtaining microbial 
MC&S results and thus directed antibiotic usage was never commenced. This 
highlights the need for possible escalation of empiric antibiotic therapy in patients 
with DNI who present with AKI, however avoidance of nephrotoxic doses is 
emphasised, notably if colistin or vancomycin, is used.  
 
6.    
 
 
 
Code 
no. 
Aerobic Anaerobic Other Antibiotic(Sensitivity) 
Antibiotic 
(Resistance) 
40 _ _ _ _ _ 
_  _ _ _ _ _ 
 
 
 
 
 
Code 
no. 
Date of 
Surgery 
Gender 
(M/F) 
Age 
(years) 
Bacterial 
Growth 
(Y/N) 
Histology 
  
(Y/N) 
Tissue 
Necrosis 
(Y/N) 
40 2014/02/26 F 71 N N (reject) _ 
_ 2014/02/26 F 71 _ (lab 
err) 
_ _ 
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The patient had an initial surgical procedure (26/02/2014). No microbial growth was 
identified on culture, thus no microbial antibiotic susceptibility testing was done. The 
source of DNI was idiopathic. The duration of hospital admission was 25/07/2014 – 
26/07/2014. The most likely cause of death was septic shock. 
 
There were 31% (n=16) of patients with “no growth” on DNI cultures and 30% (n=3) 
of patients with DNIs who demised also had “no growth” on DNI cultures. In elderly 
patients with idiopathic DNIs, with or without other immune compromising 
comorbidities, sterile MC&S results should not be taken at face value, especially in 
the context of empiric antibiotic therapy duration of less than 24 - 48 hours. One 
cannot rule out opportunistic or atypical bacterial, mycobacterial, fungal or parasitic 
DNI as causes of morbidity and mortality. In a multi – institutional study of 586 
patients with DNIs, culture-confirmed infection of C albicans, was one of the 
predictors for the development of life-threatening complications.32 
 
7.               
 
 
 
 
Code 
no. 
Aerobic Anaerobic Other Antibiotic(Sensitivity) 
Antibiotic 
(Resistance) 
33 _ _ 
GNB 
3+ 
_ _ 
34 STEMA _ _ Cotrimoxazole _ 
 
 
Code 
no. 
Date of 
Surgery 
Gender 
(M/F) 
Age 
(years) 
Bacterial 
Growth 
(Y/N) 
Histology 
  
(Y/N) 
Tissue 
Necrosis 
(Y/N) 
33 2013/05/16 M 52 N Y Y 
34 2013/05/20 M 52 Y N _ 
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The patient had an initial surgical procedure (16/05/2013) and a relook surgical 
procedure (20/05/2013). There was monomicrobial aerobic growth 
[Stenotrophomonas maltophilia (STEMA)] identified on culture with unidentified gram 
negative bacilli (GNB) isolated on microscopy only. Histology confirmed necrotising 
fasciitis. There was no reported resistance to amoxicillin – clavulanic acid; reported 
cotrimoxazole sensitivity. The source of DNI was idiopathic. The duration of hospital 
admission was 10/05/2013 – 23/05/2013. The most likely cause of death was septic 
shock. 
 
The patient demised prior to obtaining microbial MC&S results and thus directed 
antibiotic usage was never commenced. The initial surgical procedure for DNI was on 
day 6 post hospital admission, as the patient initially responded to medical 
management  including IV amoxillin – clavulanic acid. Subsequently, he developed a 
necrotizing fasciitis of the neck on day 5 post admission. Thus delays in surgical 
intervention for DNIs could possibly correlate with increased morbidity & mortality 
rates, particularly in the elderly. 
 
There were 44% (n=23) of patients with DNIs who had unidentified micro – 
organisms isolated on microscopy only, without identification on culture; 48% (n=11) 
of these patients isolated unidentified GNB on microscopy only; 60% (n=6) of 
patients with DNIs who demised isolated unidentified micro – organisms on 
microscopy only; an additional patient cultured an unidentified Bacillus species 
(BACSP); 67% (n=4) of these patients isolated unidentified GNB on microscopy only. 
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The clinical significance of unidentified micro – organisms, including gram negative 
bacilli (GNB), isolated on microscopy only, and its impact on morbidity and mortality 
rates in patients with DNI; notably in patients over the age of 40 with or without 
comorbidities, and in the context of no microbial growth identified on culture, 
deserves further research. 
  
8.  
 
 
  
Code 
no. 
        Aerobic Anaerobic Other Antibiotic(Sensitivity) 
Antibiotic 
(Resistance) 
37 _ _ 
GNB 
3+ 
_ _ 
 
The patient had an initial surgical procedure (22/09/2013). No microbial growth was 
identified on culture with unidentified GNB isolated on microscopy only. Necrotising 
fasciitis of the neck & anterior chest wall was clinically apparent but not confirmed on 
histology. Thus no microbial antibiotic susceptibility testing was done. The source of 
DNI was odontogenic. The duration of hospital admission was 20/09/2013 – 
24/10/2013. The most likely cause of death was septicaemia. Notably, the patient 
was on day 3 of colistin for Acintobacter baumanii (a GNB) septicaemia confirmed on 
blood culture. This GNB identified on blood culture was most likely the same 
unidentified GNB isolated on microscopy of the submitted DNI specimen.  
 
 
Code 
no. 
Date of 
Surgery 
Gender 
(M/F) 
Age 
(years) 
Bacterial 
Growth 
(Y/N) 
Histology 
  
(Y/N) 
Tissue 
Necrosis 
(Y/N) 
37 2013/09/22 M 50 N N _ 
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These findings are inconsistent with that of the literature.3 Apart from the delayed 
initiation of directed antibiotic treatment in this patient, routine requests for blood 
cultures, as part of the management of patients with DNIs, cannot be recommended 
based on these findings alone. 
 
9.         
 
 
 
 
 
Code 
no. 
        Aerobic Anaerobic Other Antibiotic(Sensitivity) 
Antibiotic 
(Resistance) 
19 STAHA Prevotella _ 
Vancomycin    
(aerobe). Suggested 
flagyl (anaerobe) 
Cloxacillin 
20 ACIBA Prevotella 
GPC 
3+      
GPB 
2+ 
Colistin  (aerobe) 
gentamicin; 
ceftazidime; 
piperacillin-
tazobactam; cefepime; 
amikacin; tobramycin; 
ciprofloxacin 
imipenem; 
meropenem; 
cotrimoxazole 
21 _ Prevotella 
GPB 
1+ 
_ _ 
22 _ Prevotella _ _ _ 
 
The patient had an initial surgical procedure (29/06/2011). 
Code 
no. 
Date of 
Surgery 
Gender 
(M/F) 
Age 
(years) 
Bacterial 
Growth 
(Y/N) 
Histology 
  
(Y/N) 
Tissue 
Necrosis 
(Y/N) 
19 2011/06/29 F 54 Y N (tonsil) _ 
20 2011/06/29 F 54 Y _ _ 
21 2011/06/29 F 54 Y _ _ 
22 2011/06/29 F 54 Y _ _ 
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Polymicrobial mixed aerobic and anaerobic growth [Staphylococcus haemolyticus 
(STAHA), Acinetobacter baumannii (ACIBA), Prevotella], was identified as one of 3 
pathogens per patient. Unidentified gram positive cocci (GPC) and gram positive 
bacilli (GPB) were isolated on microscopy only. This patient had 4 specimens 
submitted to the NHLS laboratory thus increasing the yield of microbes isolated and 
identified. 
  
There was no reported resistance to amoxicillin – clavulanic acid; reported 
vancomycin & colistin sensitivity. Notably, this patient clinically improved post surgical 
intervention for DNI and thus directed antibiotic therapy was not commenced. In this 
context of surgical intervention for DNI, with curative intent and that most DNIs are 
polymicrobial in nature, the role of diagnostic surgical intervention with intra - 
operative specimens submitted for MC&S analysis, can then be argued to be 
debatable, unless signs and symptoms of septicaemia are already evident or 
eminent. 
  
No routine antibiotic susceptibility testing was done for anaerobic micro-organisms. 
The source of DNI was tonsillitis. The duration of hospital admission was 29/06/2011 
– 25/08/2011. The most likely cause of death was nosocomial acquired pneumonia 
related sepsis, possibly secondary to a post tracheostomy iatrogenic trachea – 
oesophageal fistula.  
10.         
 
 
 
Code 
no. 
Date of 
Surgery 
Gender 
(M/F) 
Age 
(years) 
Bacterial 
Growth 
(Y/N) 
Histology 
  
(Y/N) 
Tissue 
Necrosis 
(Y/N) 
7 2009/04/14 M 23 Y Y  Y 
8 2009/04/14 M 23 Y _ _ 
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Code 
no. 
        Aerobic Anaerobic Other Antibiotic(Sensitivity) 
Antibiotic 
(Resistance) 
7 
_STRGF  
_CNS 
Prevotella 
GPB 
2+ 
_Penicillin/ ampicillin; 
vancomycin              
_Penicillin/ ampicillin; 
vancomycin (aerobes) 
_ 
8 STRMI Prevotella 
GPB 
1+ 
Penicillin _ 
 
The patient had an initial surgical procedure (14/04/2009). Polymicrobial mixed 
aerobic and anaerobic growth [Streptococcus Group F (STRGF), Coagulase negative 
staphylococcocus (CNS), Streptococcus milleri (STRMI), Prevotella] was identified as 
1 of 4 pathogens per patient. Unidentified gram positive bacilli (GPB) were isolated 
on microscopy only. This patient had 2 specimens submitted to the NHLS laboratory 
thus increasing the yield of microbes isolated and identified.  Histology confirmed 
necrotising fasciitis. 
 
 There was no reported resistance to amoxicillin – clavulanic acid; reported 
vancomycin sensitivity. Notably, this patient clinically improved post surgical 
intervention for DNI and thus directed antibiotic therapy was not commenced. The 
source of DNI was idiopathic. The duration of hospital admission was 12/04/2009 – 
11/05/2009. The patient was discharged from hospital 06/05/2009 and readmitted 
10/05/2009. 
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The most likely cause of death was nosocomial acquired gastroenteritis related 
sepsis with underlying acute kidney injury (was receiving dialysis) secondary to DNI. 
 
It is noted that 30% (3 /10) of patients with DNIs who demised had either 
monomicrobial [Enterococcus faecium (ENCFE)] or polymicrobial [ENCFE, 
Staphylococcus epidermidis (STAEP) & Corynebacterium species (CORSP)][ 
Staphylococcus haemolyticus (STAHA), Acinetobacter baumannii (ACIBA) & 
Prevotella]  growth patterns with reported vancomycin sensitivity. Recommended 
usage of vancomycin was as a single agent or in combination with other directed 
antibiotics, in this instance, colistin. The use of vancomycin & colistin either as single 
agents, or in combination, as empiric antibiotics in patients with DNIs & whether this 
will significantly affect mortality rates, needs further research.  
 
3.8 Sources of DNIs in Survivors versus Patients with DNIs who Demised 
 
The sources of DNI in that of survivors, was idiopathic (52%) in most instances, 
followed by odontogenic origin (26%). In patients who demised, secondary to DNIs, 
odontogenic sources (60%) was most frequently encountered.1 There were 32% of 
survivors of DNI of idiopathic sources who were retroviral disease positive. One 
survivor of DNI of idiopathic source, was a patient with GPA in remission, secondary 
to iatrogenic immunosuppressive steroid therapy. Salmonella from idiopathic sources 
was identified in 4% (n=2) of patients with DNIs; who were interestingly also newly 
diagnosed with diabetes mellitus type II, in keeping with the literature.2,24  Thus the 
role of underlying host immunity, or rather lack therof, in DNIs, including that from 
idiopathic sources, is emphasized. 
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Figure 3.9 Sources of DNIs in Survivors 
                                                                      97 
 
            Figure 3.10 Sources of DNIs in patients who demised 
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4 SUMMARY, CONCLUSION AND RECOMMENDATIONS 
 
4.1 Summary 
 
Admissions of patients with DNIs significantly increased during the latter period of the 
study (07/2012 – 06/2015). There was a 19% mortality rate, with an odontogenic 
source of DNI in 60% of patients who demised and in 26% of survivors, respectively. 
In 52% of survivors, the source of DNI was idiopathic.  The distribution of positive 
cultures was 69% (n=48) and that of negative cultures- implying no growth, was 31% 
(n=22), from 70 specimens of 52 patients with DNIs. There were 66% (n=23) of 
patients with positive cultures who had monomicrobial growth identification with 
polymicrobial growth in 34% (n=12); aerobes only were identified in 89% (n=31) and 
both aerobes and anaerobes identified in 11% (n=4). There were 92% (n=24) of 
microorganisms which were aerobic and 8% (n=2) anaerobic. When all pathogens 
were considered, 60% (n=34) had polymicrobial growth patterns and 40% (n=23) 
monomicrobial growth; 93% (n= 53) were aerobic and 7% (n=4) anaerobic; 57 
microorganisms were identified on culture as 26 different microorganism subtypes in 
35 patients with positive cultures. 
 
The distribution of negative cultures in this study, relative to the literature, was not 
negligible (31% versus 19% respectively); in patients with positive cultures; when all 
micro-organisms were considered, polymicrobial and aerobic growth patterns were 
more common than monomicrobial and anaerobic growth identification; whether this 
represents a true reflection of anaerobes involved in DNIs or an underestimation; 
requires further clarification.  
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In descending order, aerobic ACIBA, Streptococcus pyogenes (STRPY), 
Streptococcus anginosus (STRAN), Enterococcus faecalis / Enterococcus faecium 
(ENTFA/ENCFE); Coagulase negative staphylococcocus (CNS), Streptococcus 
Group F (STRGF), Streptococcus milleri (STRMI), Klebsiella (KLESP); and anaerobic 
Prevotella, were the more frequently isolated and identified micro – organisms in 
adult patients with DNIs at CHBAH. Thus, the most frequently isolated aerobic 
microorganisms included gram negative bacilli and streptococcus species. Although 
infrequently encountered; atypical micro – organisms in this patient population 
included fungi, TB and salmonella.  
 
The study hypothesis is that the empiric antibiotic therapy currently in use, amoxicillin 
– clavulanic acid, is effective against microbes commonly involved in DNIs in adults 
at CHBAH. Utilising this report as a retrospective tool to guide empiric antibiotic 
usage; the small study population number and that suggestions are primarily based 
on inferences only; is emphasized: In retrospective review, this hypothesis cannot be 
proved nor disproved: It is suggested from this study that the empiric antibiotics used 
as part of the management of adult patients with DNIs at CHBAH should idealistically 
include those that are effective against the most frequently isolated microorganisms, 
although this might not always be feasible, nor practical. 
 
Notably concerning was the ratio of reported amoxicillin – clavulanic acid resistance : 
sensitivity of 7:1 in the final year of the study (07/2014 – 06/2015); and that this 
antimicrobial resistance profile was specific to identified gram negative bacilli (GNB) 
on patient specimen cultures: These micro – organisms, namely extended spectrum 
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beta lactamase producing Klebsiella (ESBL KLESP), Enterobacter cloacae (ENTCL), 
Serratia marcescens (SERMA), Citrobacter freundii (CITFR) and Morganella 
morganii (MOGMO), were not amongst those most frequently isolated and identified 
in adult patients with DNIs at CHBAH - 5 of 26 identified microbes (19%), resistant to 
amoxicillin – clavulanic acid; 7 of 57 microbes (12%). The significance of  the 
increase in the reported resistance to amoxicillin – clavulanic acid   cannot be 
ascertained due to the small numbers of the study population tested. 
    
 Klebsiella (KLESP) and Escherichia coli (ESCCO), both gram negative bacilli (GNB), 
were the only 2 of 26 identified microbes (8%) with reported sensitivity to amoxicillin – 
clavulanic acid; 3 of 57 microbes (5%) when all pathogens were considered.  
Microbial sensitivity to amoxicillin – clavulanic acid was reported in only 3 of the 52 
patients (6%) and that of microbial resistance in only 5 patients (10%) of the total 
study population. It is thus emphasized that profiles of microbial sensitivity and 
resistance to amoxicillin – clavulanic acid was reported in only 15% (n = 8) of patients 
with DNIs. 
 
In this study, when microbial resistance to amoxicillin – clavulanic acid was 
encountered, recommended alternative antimicrobial coverage included: Ertapenem 
effective against Morganella morganii (MOGMO), Citrobacter freundii (CITFR), 
Enterobacter cloacae (ENTCL), Serratia marcescens (SERMA) and extended 
spectrum beta - lactamase producing Klebsiella  ESBL KLESP; cefepime effective 
against MOGMO, ENTCL and SERMA; piperacillin – tazobactam effective against 
MOGMO and ENTCL and Ciprofloxacin was effective against ENTCL and SERMA.  
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Acinetobacter baumannii (ACIBA) accounted for 53% (n=48) of cases of antibiotic 
resistance with that to Ceftazidime  and Ciprofloxacin approached 57% and 67%, 
respectively. Colistin was effective against ACIBA with reported multiple drug 
resistance. Amoxicillin – clavulanic acid & Cefotaxime/Ceftriaxone were effective 
against Klebsiella (KLEBS), with equivalent susceptibility and associated resistance 
profiles of 67% and 33%, respectively. When only  reported antimicrobial sensitivity 
profiles were considered, that of klebsiella to ertapenem was 20%. Ertapenem was 
effective against polymicrobial growth of ESBL KLESP with  multiple drug resistant 
ACIBA and Streptococcus viridans (STRVI); with associated resistance to amoxicillin 
– clavulanic acid and cefotaxime/ceftriaxone. Recommended alternative antibiotic 
usage entailed escalated dual therapy consisting of a combination of colistin (a 
polymyxin) and ceftriaxone for the treatment of all 3 microorganisms. 
  
Penicillin/ampicillin was effective against Streptococcus anginosus (STRAN), 
Coagulase negative staphylococcocus (CNS), Streptococcus Group F (STRGF), 
Streptococcus milleri (STRMI) and Streptococcus pyogenes (STRPY), with a 
sensitivity of 100%, 67%, 60%, 75% and 83%, respectively; that of STRGF and                                                                                                                                                                                            
STRPY to clindamycin was 20% and 17%, respectively; and that of STRMI to 
cefotaxime/ ceftriaxone  was 25% . Vancomycin was effective against polymicrobial 
growth that included STRPY with Staphylococcus haemolyticus (STAHA); and 
against that of Enterococcus faecium (ENTFA/ENCFE) with Coagulase negative 
staphylococcocus (CNS); ENCFE with Staphylococcus epidermidis (STAEP) and an 
unidentified Bacillus species (BACSP); ENCFE and Gram negative bacilli (GNB) on 
microscopy only, respectively; with associated resistance to penicillin/ampicillin. 
ENTFA/ENCFE sensitivity to vancomycin was 75% (n=3). 
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TB and fungal DNIs are relatively uncommon: In 8% of patients with DNIs, 
extrapulmonary TB was suggested clinically and or radiologically; with no growth on 
culture in 75%, no AFBs detected on microscopy in 50%, AFB positive on culture and 
mycobacterium complex detected on PCR in 25%. Therapeutic and empiric anti-TB 
therapy was initiated in 25% and 50% of patients, respectively. In 4% of patients, 
fungal DNIs was confirmed on subculture and on histology in 50% of these patients, 
respectively. Further, with regards to atypical micro-organisms isolated in patients 
with DNIs, Salmonella was identified in 4% of patients who were also newly 
diagnosed with diabetes mellitus type II. 
 
4.2 Conclusion 
 
Patients with DNIs at CHBAH treated with the combined modalities of surgical 
intervention and empiric antibiotic usage, currently amoxicillin – clavulanic acid, has 
resulted in an overall favourable outcome associated with a low mortality rate of 19%.   
In this study, when microbial resistance to amoxicillin – clavulanic acid was 
encountered, suggested alternative antimicrobial agents included third or fourth 
generation cephalosporins, polymyxins or carbapenems; either as single agents or 
as combination therapy. Flouroquinolones and other beta – lactamase resistant 
penicillins were also favoured alternatives. However, alternative empiric antibiotic 
usage cannot be recommended, based on this study. 
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4.3 Recommendations 
 
The epidemiology of DNIs needs to be monitored for changing trends and the impact 
of underlying host immunity and developing microbial multi-drug resistance, 
established. Surveillance at a NHLS  level should include mandatory susceptibility 
testing of all microbes commonly identified in adult DNI MC&S specimens, to the then 
current loco- regional empiric antibiotics in use. The role of susceptibility testing of 
microbes not commonly identified in adult DNI MC&S specimens, to the then current 
loco- regional empiric antibiotics in use, needs further review, in selected patients on 
a clinical case by case basis. Thus for this study population at CHBAH, the 
antimicrobial agent test battery should  include routine amoxicillin – clavulanic acid 
susceptibility testing. This also serves as a method of standardization which has 
reproducibility and can be used in comparative analysis.  
 
A key factor in ensuring adequate empiric antibiotic coverage, would be to elucidate 
the clinical significance and impact on morbidity and mortality rates, of idiopathic 
sources of DNIs amongst other sources, unidentified microbes, isolated on 
microscopy only but not cultured, with particular emphasis on unidentified gram 
negative bacilli (GNB) ,  that of “no growth” & polymicrobial growth patterns; including 
the relevance and cost versus benefit of intra – operative DNI specimen collection in 
guiding directed antibiotic usage.  
 
Further research must also provide a superior quality of evidence in routinely 
monitoring & analyzing trends of common micro – organisms implicated in adults with 
DNIs including that isolated in patients with DNIs who demised and empiric antibiotic 
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usage patterns in adults with DNIs, with intent to periodically update practice 
guidelines at a regional and even national health level, thereby deterring multidrug 
resistance, in part contributing to the management of patients with DNIs. To ensure 
an adequate patient population, a sequel to this study should  possibly include 
Charlotte Maxeke and Helen Joseph  academic hospitals, which are affiliated to the 
University of the Witwatersrand, in the surveillance program as well.   
 
The recommendation for continued empiric usage of amoxicillin – clavulanic acid as 
well as that of appropriate alternative empiric antibiotic usage; in this study 
population, requires further periodic surveillance of commonly identified microbes 
and antimicrobial sensitivity results; utilizing standardized protocols. The increase in 
the reported resistance to amoxicillin – clavulanic acid, particularly in uncommonly 
identified gram negative bacilli (GNB); as well as polymicrobial growth patterns and 
its influence on antimicrobial sensitivity, also requires further elucidation.  
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6 APPENDICES 
 
6.1 Appendix IA – Linked Secured File 1 
  
Code Date of Gender Age Bacterial Histology Tissue 
        Growth   Necrosis 
No. Surgery (M/F) (years) (Y/N) (Y/N) (Y/N) 
1   
2008/07/21 
F 21 Y N (PNS) _ 
2 2008/12/11 M 27 N N _ 
3 2008/12/11 M 27 N _ _ 
4 2008/12/24 F 21 N N _ 
5 2009/02/20 F 27 Y Y N 
6 2009/02/26 F 29 N N _ 
7 2009/04/14 M 23 Y Y  Y 
8 2009/04/14 M 23 Y _ _ 
9 2010/01/29 M 28 N Y Y 
10 2010/02/17 M 30 Y N _ 
11 2010/03/28 F 31 Y N _ 
12 2010/04/04 F 28 N N _ 
13 2010/04/04 F 28 N _ _ 
14 2011/02/05 M 28 Y N _ 
15 2011/02/21 F 52 Y N _ 
16 2011/03/12 M 34 Y N _ 
17 2011/05/17 M 50 N N _ 
18 2011/06/23 F 57 N N _ 
19 2011/06/29 F 54 Y N (tonsil) _ 
20 2011/06/29 F 54 Y _ _ 
21 2011/06/29 F 54 Y _ _ 
22 2011/06/29 F 54 Y _ _ 
23 2012/04/24 M 35 Y N _ 
24 2012/07/31 M 30 Y N _ 
25 2012/09/13 M 33 N Y Y 
26 2012/12/23 M 36 Y N _ 
27 2012/12/23 M 36 N _ _ 
28 2013/02/26 M 24 Y Y Y 
29 2013/03/23 F 57 Y N 
(mastoid)                 
_ 
30 2013/03/23 F 57 Y _ _ 
31 2013/04/16 M 36 Y Y Y 
32 2013/04/16 M 36 N _ _ 
33 2013/05/16 M 52 N Y Y 
34 2013/05/20 M 52 Y N _ 
35 2013/06/13 M 39 Y N _ 
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  36 2013/07/25 F 19 Y Y Y 
37 2013/09/22 M 50 N N _ 
38 2013/10/26 M 42 N N _ 
39 2013/12/13 M 53 Y N _ 
40 2014/02/26 F 71 N N (reject) _ 
_ 2014/02/26 F 71 _ (lab 
err) 
_ _ 
41 2014/03/17 F 43 Y N _ 
42 2014/03/27 M 61 Y Y Y 
43 2014/03/27 M 61 Y _ _ 
44 2014/03/29 M 61 Y N _ 
45 2014/05/07 M 50 Y N _ 
46 2014/05/17 M 22 N N _ 
47 2014/08/14 F 74 Y N _ 
48 2014/08/19 F 74 Y N _ 
49 2014/08/21 M 57 Y Y Y 
50 2014/09/03 F 30 N N _ 
51 2014/09/13 F 42 N Y N 
52 2014/09/29 M 42 Y Y Y 
53 2014/10/02 M 35 N N _ 
54 2014/10/02 M 39 Y N _ 
55 2014/10/02 M 39 Y _ _ 
56 2014/10/28 F 68 Y N _ 
57 2014/10/30 M 53 Y N _ 
58 2014/10/30 M 20 Y N _ 
59 2014/11/28 M 53 Y Y Y 
60 2014/12/14 F 45 Y N _ 
61 2014/12/19 M 22 Y Y Y 
62 2014/12/23 M 22 Y Y Y 
63 2014/12/23 M 22 Y _ _ 
64 2014/12/26 F 64 Y N _ 
65 2015/01/30 M 52 N N _ 
66 2015/02/05 M 39 N N (lab 
error) 
_ 
67 2015/02/09 M 39 Y N _ 
68 2015/03/07 M 20 Y N _ 
69 2015/06/21 M 77 Y Y Y 
70 2015/06/22 M 77 Y Y Y 
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6.2 Appendix IB – Linked Secured File 2 
 
   
Code no. Aerobic Anaerobic Other Antibiotic (Sensitivity) Antibiotic (Resistance) 
1 
CANAL 
(subculture) 
_ GPC + _ _ 
2 _ _ GPC 2+ _ _ 
3 _ _ 
GNB 
(mixed 
enteric) 
_ _ 
4 _ _ _ _ _ 
5 STRMI _ GNB 3+ Penicillin _ 
6 _ _ _ _ _ 
7 
_STRGF  
_CNS 
Prevotella GPB 2+ 
_Penicillin/ ampicillin; 
vancomycin              
_Penicillin/ ampicillin; 
vancomycin (aerobes) 
_ 
8 STRMI Prevotella GPB 1+ Penicillin _ 
9 _ _ GPC 3+ _ _ 
10 STRGF _ _ 
Penicillin/ ampicillin; 
clindamycin 
_ 
11 STRMI Prevotella GPB 2+ 
Penicillin (aerobes); 
cefotaxime/ ceftriaxone 
_ 
12 _ _ _ _ _ 
13 _ _ _ _ _ 
14 STRGF _ GPB 2+ Penicillin/ ampicillin _ 
15 Salmonella _ _ 
Ceftriaxone/ cefotaxime; 
ciprofloxacin 
_ 
16 STRVI _ _ Penicillin _ 
17 _ _ GNB 1+ _ _ 
18 _ _ _ _ _ 
19 STAHA Prevotella _ 
Vancomycin    (aerobe). 
Suggested flagyl 
(anaerobe) 
Cloxacillin 
101 
 
20 ACIBA Prevotella 
GPC 3+      
GPB 2+ 
Colistin  (aerobe) 
gentamicin; ceftazidime; 
piperacillin-tazobactam; 
cefepime; amikacin; 
tobramycin; ciprofloxacin 
imipenem; meropenem; 
cotrimoxazole 
21 _ Prevotella GPB 1+ _ _ 
22 _ Prevotella _ _ _ 
23 STRPY _ _ Penicillin/ ampicillin _ 
24 STAAU _ _ Cloxacillin _ 
25 _ _ GPC 3+ _ _ 
26 
AFB&MTB 
(on PCR) 
_ _  INH/rifampicin _ 
27 _ _ _ _ _ 
28 STRAN _ GNB 3+ Penicillin/ ampicillin _ 
29 Klebsiella _ _ 
amoxicillin-clavulanic 
acid; cefotaxime/ 
ceftriaxone 
Ampicillin/ amoxicillin 
30 
_ENTFA  
_ACIBA 
_ _ 
_ Penicillin/ ampicillin 
_Ceftazidime _                                                                                              
_piperacillin-tazobactam; 
cefepime; imipenem; 
meropenem       
31 CNS _ _ Penicillin/ ampicillin _ 
32 _ _ G+C 3+ _ _ 
33 _ _ GNB 3+ _ _ 
34 STEMA _ _ Cotrimoxazole _ 
35 STRAN _ _ Penicillin/ ampicillin _ 
36 
GPC (non 
viable) 
_ 
GPC 3+ 
GPB 2+ 
_ _ 
37 _ _ 
GNB 3+ 
GPC 1+ 
_ _ 
38 _ _ _ _ _ 
39 SALSP _ _ Ceftriaxone/ cefotaxime _ 
40 _ _ _ _ _ 
_  _ _ _ _ _ 
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41 
-STAHA                 
-HAEPA            
-STRPY 
_ _ 
_Vancomycin  
_Ampicillin/ amoxicillin      
_Penicillin/ ampicillin 
_Penicillin/ ampicillin; 
cloxacillin                                                           
_                                         
_                                                       
42 KLESP _ _ 
amoxicillin-clavulanic   
acid; cefotaxime/ 
ceftriaxone                              
Ampicillin/ amoxicillin 
43 ACIBA _ _ Colistin 
_piperacillin/ tazobactam; 
ciprofloxacin; ceftazidime; 
cefepime; gentamicin; 
imipenem; meropenem  
44 ACIBA _ _ Colistin 
 _piperacillin/ tazobactam; 
trimethoprim-
sulfamethoxazole; 
ciprofloxacin; ceftazidime; 
cefepime; gentamicin; 
tobramycin; imipenem; 
meropenem                    
45 
_ CNS               
_ENCFE 
_ _ 
_vancomycin 
_vancomycin 
_Penicillin/ ampicillin; 
cloxacillin        
_ampicillin/ amoxicillin 
46 _ _ GPC 3+ _ _ 
47   _  
                                           
_vancomycin   
_vancomycin  
_ampicillin/ amoxicillin    
_Penicillin/ ampicillin; 
cloxacillin; erythromycin/ 
azithromycin; clindamycin; 
trimethoprim-
sulfamethoxazole  
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_ENCFE 
_STAEP  
_ BACSP 
(light 
growth)                  
48 CORSP CORSP _ _ _ 
49 ESCCO _ _ amoxicillin-clavulanic acid                                 _ 
50 _ _ _ _ _ 
51 _ _ 
GPC 2+ 
GNB 2+ 
_ _ 
52 ENCFE _ G–B 2+ Vancomycin Ampicillin/ amoxicillin 
53 _ _ _ _ _ 
54 STRPY _ _ Penicillin/ ampicillin _ 
55 STRPY _ _ Penicillin/ ampicillin _ 
56 
_ACIBA 
_ _ 
_colistin                   
_ertapenem              
_cefotaxime/ ceftriaxone 
(colistin & ceftriaxone  
combination for all 3 
microorganisms)  
_ trimethoprim-
sulfamethoxazole; 
ciprofloxacin; ceftazidime; 
cefepime; gentamicin 
piperacillin/ tazobactam; 
imipenem; meropenem 
_ ESBL 
KLESP 
_STRVI 
  
_ trimethoprim-
sulfamethoxazole;ampicillin/ 
amoxicillin; amoxicillin-
clavulanic acid;cefazolin; 
cefuroxime; cefotaxime/ 
ceftriaxone; ceftazidime; 
cefepime        
 _ 
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57 STRSP _ 
G – B 
3+ 
Ceftriaxone/ cefotaxime _ 
58 
STRSP         
(N/S –Spp) 
__ _ Ceftriaxone/ cefotaxime _ 
59 
_SERSP                     
_ENTCL 
_ _ 
_piperacillin/ tazobactam 
cefepime              
_piperacillin/ tazobactam; 
cefepime 
_ampicllin/ amoxicillin                       
_ amoxicillin-clavulanic 
acid;ampicillin/ amoxicillin 
60 STRPY _ _ 
Penicillin/ ampicillin; 
clindamycin 
_ 
 
61 STRAN _ 
GPB 1+ 
GNB 3+ 
Penicillin _ 
62 
_ENTCL 
_ _ 
_ciprofloxacin; cefepime; 
ertapenem  
_ciprofloxacin           
_ciprofloxacin; cefepime; 
ertapenem 
                                                 
_ amoxicillin-clavulanic 
acid;ampicillin/ amoxicillin                                
_piperacillin/ tazobactam; 
trimethoprim-
sulfamethoxazole; 
meropenem                         
_amoxicillin-clavulanic 
acid;ampicillin/ amoxicillin 
_ACIBA             
_SERMA 
63 ACIBA _ _ Ciprofloxacin;ceftazidime 
Piperacillin/ tazobactam ;  
meropenem; imipenem 
64 STRAN _ 
G – B 
2+ 
Penicillin/ ampicillin _ 
65 _ _ _ _ _ 
66 _ _ GPC 3+ _ _ 
67 
                          
_CITFR                
_ACIBA  
_ _ 
_Ertapenem            
_Ceftazidime 
_amoxicillin-clavulanic 
acid;ampicillin/ 
amoxicillin;cefuroxime; 
ceftazidime                                                                   
_piperacillin/ tazobactam ; 
meropenem;cefepime; 
imipenem    
68 STAAU _ _ 
Cloxacillin; 
erythromycin/azithromycin 
Penicillin/ ampicillin 
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69 MOGMO _ 
GPC 3+ 
(lost 
viability) 
Ertapenem; cefepime 
amoxicillin-clavulanic acid; 
trimethoprim-
sulfamethoxazole; 
ampicillin/ amoxicillin; 
cefazolin; gentamicin 
70 MOGMO _ 
GPC 3+ 
(lost 
viability) 
piperacillin/ tazobactam 
amoxicillin-clavulanic 
acid;ampicillin/amoxicillin                                 
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